WO2021040496A1 - 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물 - Google Patents
백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물 Download PDFInfo
- Publication number
- WO2021040496A1 WO2021040496A1 PCT/KR2020/011648 KR2020011648W WO2021040496A1 WO 2021040496 A1 WO2021040496 A1 WO 2021040496A1 KR 2020011648 W KR2020011648 W KR 2020011648W WO 2021040496 A1 WO2021040496 A1 WO 2021040496A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccinia virus
- cancer
- administered
- virus
- administration
- Prior art date
Links
- 241000700618 Vaccinia virus Species 0.000 title claims abstract description 367
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 258
- 239000003112 inhibitor Substances 0.000 title claims abstract description 136
- 201000011510 cancer Diseases 0.000 title claims abstract description 116
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 40
- 239000004480 active ingredient Substances 0.000 title claims abstract description 25
- 230000001093 anti-cancer Effects 0.000 claims abstract description 192
- 230000015572 biosynthetic process Effects 0.000 claims description 130
- 210000000265 leukocyte Anatomy 0.000 claims description 117
- 239000008187 granular material Substances 0.000 claims description 113
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 69
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 69
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 69
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 69
- 239000000203 mixture Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 47
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 239000003814 drug Substances 0.000 claims description 40
- 210000000440 neutrophil Anatomy 0.000 claims description 40
- 238000011282 treatment Methods 0.000 claims description 36
- 108020004440 Thymidine kinase Proteins 0.000 claims description 31
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 29
- 206010006187 Breast cancer Diseases 0.000 claims description 28
- 208000026310 Breast neoplasm Diseases 0.000 claims description 28
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 24
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims description 24
- 229960004942 lenalidomide Drugs 0.000 claims description 23
- 206010009944 Colon cancer Diseases 0.000 claims description 14
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 14
- 239000002671 adjuvant Substances 0.000 claims description 14
- 208000029742 colonic neoplasm Diseases 0.000 claims description 14
- 210000003714 granulocyte Anatomy 0.000 claims description 14
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 13
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 claims description 13
- 229960004390 palbociclib Drugs 0.000 claims description 13
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 12
- 229960004857 mitomycin Drugs 0.000 claims description 12
- 229960003048 vinblastine Drugs 0.000 claims description 12
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 229940123237 Taxane Drugs 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims description 11
- 239000005557 antagonist Substances 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 10
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 claims description 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 8
- 210000000224 granular leucocyte Anatomy 0.000 claims description 8
- 241000700584 Simplexvirus Species 0.000 claims description 7
- 229940100198 alkylating agent Drugs 0.000 claims description 7
- 239000002168 alkylating agent Substances 0.000 claims description 7
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 7
- 230000002503 metabolic effect Effects 0.000 claims description 7
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 7
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 101800003344 Vaccinia growth factor Proteins 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229960003433 thalidomide Drugs 0.000 claims description 6
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 108010051152 Carboxylesterase Proteins 0.000 claims description 5
- 102000013392 Carboxylesterase Human genes 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 206010017758 gastric cancer Diseases 0.000 claims description 5
- 230000004060 metabolic process Effects 0.000 claims description 5
- 230000002441 reversible effect Effects 0.000 claims description 5
- 201000011549 stomach cancer Diseases 0.000 claims description 5
- 229960000835 tadalafil Drugs 0.000 claims description 5
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 208000000728 Thymus Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 201000010175 gallbladder cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 201000009377 thymus cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 101150096316 5 gene Proteins 0.000 claims 1
- 101150011225 5L gene Proteins 0.000 claims 1
- 101150006352 B18R gene Proteins 0.000 claims 1
- 101150039660 HA gene Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 216
- 210000004027 cell Anatomy 0.000 description 211
- 241000700605 Viruses Species 0.000 description 177
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 164
- 229960001330 hydroxycarbamide Drugs 0.000 description 160
- 241000699666 Mus <mouse, genus> Species 0.000 description 118
- 208000008839 Kidney Neoplasms Diseases 0.000 description 77
- 206010038389 Renal cancer Diseases 0.000 description 77
- 201000010982 kidney cancer Diseases 0.000 description 77
- 238000002513 implantation Methods 0.000 description 64
- 239000013641 positive control Substances 0.000 description 42
- 229940079593 drug Drugs 0.000 description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 239000011780 sodium chloride Substances 0.000 description 29
- 230000006978 adaptation Effects 0.000 description 28
- 239000013642 negative control Substances 0.000 description 28
- 238000002360 preparation method Methods 0.000 description 26
- 238000011260 co-administration Methods 0.000 description 25
- 238000012790 confirmation Methods 0.000 description 24
- 239000012271 PD-L1 inhibitor Substances 0.000 description 23
- 238000010586 diagram Methods 0.000 description 23
- 229940121656 pd-l1 inhibitor Drugs 0.000 description 23
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 22
- 229940045513 CTLA4 antagonist Drugs 0.000 description 22
- 101150003725 TK gene Proteins 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 230000035755 proliferation Effects 0.000 description 17
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000002601 intratumoral effect Effects 0.000 description 14
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 210000000952 spleen Anatomy 0.000 description 11
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 9
- 239000012270 PD-1 inhibitor Substances 0.000 description 8
- 239000012668 PD-1-inhibitor Substances 0.000 description 8
- 238000011394 anticancer treatment Methods 0.000 description 8
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 8
- 238000001647 drug administration Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 229940121655 pd-1 inhibitor Drugs 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 210000004988 splenocyte Anatomy 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000010172 mouse model Methods 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000002730 additional effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 201000005787 hematologic cancer Diseases 0.000 description 6
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 5
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 5
- 208000034578 Multiple myelomas Diseases 0.000 description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 description 5
- 101150004676 VGF gene Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000001361 intraarterial administration Methods 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004721 adaptive immunity Effects 0.000 description 4
- -1 alkyl sulfonic acid derivative Chemical class 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 229960003301 nivolumab Drugs 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 210000005084 renal tissue Anatomy 0.000 description 4
- 239000013605 shuttle vector Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 108090000331 Firefly luciferases Proteins 0.000 description 3
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 3
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- 210000003651 basophil Anatomy 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 3
- 210000003979 eosinophil Anatomy 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003862 health status Effects 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 210000000066 myeloid cell Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 2
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000881059 Vaccinia virus Wyeth Species 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000001046 cacaotero Nutrition 0.000 description 2
- 229940127093 camptothecin Drugs 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- 230000005880 cancer cell killing Effects 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940044683 chemotherapy drug Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940096120 hydrea Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008718 systemic inflammatory response Effects 0.000 description 2
- 229950008461 talimogene laherparepvec Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- LPXQRXLUHJKZIE-UHFFFAOYSA-N 8-azaguanine Chemical compound NC1=NC(O)=C2NN=NC2=N1 LPXQRXLUHJKZIE-UHFFFAOYSA-N 0.000 description 1
- 229960005508 8-azaguanine Drugs 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 description 1
- 101150023320 B16R gene Proteins 0.000 description 1
- 0 C*(CC(*([C@](C(*1(C)C)=C(C2)c3c1cccc3)c(cc1)cc3c1OCO3)[C@]21I)=O)C1=O Chemical compound C*(CC(*([C@](C(*1(C)C)=C(C2)c3c1cccc3)c(cc1)cc3c1OCO3)[C@]21I)=O)C1=O 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241001493160 California encephalitis virus Species 0.000 description 1
- 241000759909 Camptotheca Species 0.000 description 1
- 241000759905 Camptotheca acuminata Species 0.000 description 1
- 241001247439 Chonemorpha fragrans Species 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical class C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 206010052399 Neuroendocrine tumour Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 244000236480 Podophyllum peltatum Species 0.000 description 1
- 235000008562 Podophyllum peltatum Nutrition 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108050001286 Somatostatin Receptor Proteins 0.000 description 1
- 102000011096 Somatostatin receptor Human genes 0.000 description 1
- 101150038447 Sstr2 gene Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000187392 Streptomyces griseus Species 0.000 description 1
- 241000187081 Streptomyces peucetius Species 0.000 description 1
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 description 1
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 description 1
- 241000863480 Vinca Species 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009692 acute damage Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000009613 breast lymphoma Diseases 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940075117 droxia Drugs 0.000 description 1
- 230000005584 early death Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000016065 neuroendocrine neoplasm Diseases 0.000 description 1
- 201000011519 neuroendocrine tumor Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000005727 virus proliferation Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/12—Animals modified by administration of exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a pharmaceutical composition for the treatment of cancer comprising a vaccinia virus and an inhibitor of granule leukocyte formation as an active ingredient.
- Anti-cancer virus has excellent tumor-specific targeting ability, proliferation ability in cancer cells, and cancer cell killing ability, and a variety of clinical studies based on anti-cancer viruses are recently being conducted.
- T-Vec talimogene laherparepvec
- an anticancer virus based on the herpes simplex virus in the United States and Europe as a treatment for advanced melanoma.
- vaccinia virus-based anticancer viruses after anticancer virus treatment, acute tumor necrosis, durable response, or complete response may appear, but sometimes tumor progression (progressive disease). ) Or early death, leading to unpredictable outcomes (pharmacodynamics variability).
- Pexa-vec which is based on vaccinia virus, it is related to continuous systemic inflammatory response and organ dysfunction after anticancer virus treatment in a phase 1 clinical trial. Some patients died prematurely within a month.
- transient flu symptoms (high fever) and hypotension after anti-cancer virus treatment are the most frequent adverse reactions of anti-cancer virus treatment.
- neutrophils are the first innate immune cells in the human body, which have a short half-life of less than 20 hours in the body.
- drugs such as clozapine, acute inflammation, and acute injury (Liao Y et al , PloS One , 8(7), 2013), but this is a general adverse reaction category (Common Terminology Criteria of Adverse Events (CTCAE), so increased absolute neutrophil count (ANC) is not recognized as an abnormal response.
- CCAE Common Terminology Criteria of Adverse Events
- the present inventors studied to enhance the anticancer effect of vaccinia virus, which is used as an anticancer virus, when vaccinia virus is administered to an individual with cancer, when an inhibitor that lowers the neutrophil count is used in combination with the existing vaccinia virus.
- the present invention was completed by confirming that the systemic inflammatory response can be significantly reduced compared to the case of administering only, and furthermore, when the inhibitor is administered in combination, the cancer cell-specific selectivity and proliferation ability of vaccinia virus are improved.
- the inhibitor is thought to improve the anticancer effect of the anticancer virus by lowering the neutrophil count by inhibiting granulopoiesis.
- an aspect of the present invention provides a pharmaceutical composition for treating cancer comprising a vaccinia virus and an inhibitor of granule leukocyte formation as an active ingredient.
- Another aspect of the present invention provides a method for treating cancer comprising administering a vaccinia virus and an inhibitor of granulocyte formation to an individual suffering from cancer.
- Another aspect of the present invention provides the use of a composition comprising a vaccinia virus and an inhibitor of granulocyte formation for preventing or treating cancer.
- compositions comprising a vaccinia virus granulocyte formation inhibitor for preparing a medicament for the prevention or treatment of cancer.
- Another aspect of the present invention provides an anticancer adjuvant comprising an inhibitor of granule leukocyte formation as an active ingredient.
- the pharmaceutical composition for cancer treatment comprising the vaccinia virus and granule leukocyte formation inhibitor of the present invention as an active ingredient has superior anticancer effect and safety compared to the case of administering only the existing vaccinia virus. Therefore, the pharmaceutical composition comprising the vaccinia virus and the granule leukocyte formation inhibitor of the present invention as an active ingredient can be usefully used to treat cancer.
- FIG. 2 is a diagram showing body weights measured on days 0, 3, 7, 10 and 14 after administration of wild-type vaccinia virus (WR) and HU to mouse-renal cancer cells (Renca)-embedded mice.
- WR wild-type vaccinia virus
- Renca mouse-renal cancer cells
- Figure 4 is a mouse-renal cancer cell (Renca) -after administration of the recombinant vaccinia virus (WR VV tk-) and HU (30 mg/kg) to the mouse, 0 days, 3 days, 7 days, 10 days and 14 It is a diagram measuring the size of the tumor on the first day.
- VV_DD recombinant vaccinia virus
- VVF vaccinia virus growth factor
- Figure 6 shows the size of tumors on days 0, 5, 10, 12 and 15 after administration of recombinant vaccinia virus (WOTS-418) and HU to human-lung cancer cells (NCI-H460)-embedded mice. It is a figure which measured.
- Fig. 7 is a diagram showing the survival rate after administration of recombinant vaccinia virus (WOTS-418) and HU to human-lung cancer cells (NCI-H460)-embedded mice.
- Figure 8 is a diagram of measuring the tumor size of a mouse after administration of a recombinant vaccinia virus (VV tk- ) and a human granulocyte colony stimulating factor (rhG-CSF) or HU to a mouse-renal cancer cell (Renca)-embedded mouse. to be.
- VV tk- recombinant vaccinia virus
- rhG-CSF human granulocyte colony stimulating factor
- Renca mouse-renal cancer cell
- Figure 9 is a mouse administered with recombinant vaccinia virus (VV tk- ) and human granulocyte colony stimulating factor (rhG-CSF) or HU-lymphocytes in the spleen isolated from renal cancer cells (Renca)-embedded mice are administered to a new mouse. After that, the size of the tumor of a new mouse was measured.
- VV tk- recombinant vaccinia virus
- rhG-CSF human granulocyte colony stimulating factor
- Renca HU-lymphocytes
- Fig. 10 is a diagram showing the size of a tumor of a mouse after administration of a recombinant vaccinia virus (Wyeth VV tk- ) and HU to a mouse-renal cancer cell (Renca)-embedded mouse.
- FIG. 11 is a diagram showing the tumor size of a new mouse after administration of T lymphocytes isolated from a mouse-renal cancer cell (Renca)-embedded mouse administered with recombinant vaccinia virus (Wyeth VV tk-) and HU to a new mouse. It is a drawing.
- Figure 12 is a mouse-renal cancer cells (Renca) administered with recombinant vaccinia virus (Wyeth VV tk- ) and HU-implanted splenocytes isolated from mice were administered to a new mouse, and then the tumor size of the new mouse was measured. It is a drawing.
- FIG. 13 is a diagram showing the size of a tumor on day 22 after administration of a recombinant vaccinia virus (Wyeth VV tk- ) and HU to a mouse-renal cancer cell (Renca)-embedded mouse.
- FIG. 14 is a diagram illustrating the degree of proliferation of CD4+ T cells or CD8+ T cells in spleen tissue after administration of recombinant vaccinia virus (Wyeth VV tk- ) and HU to mouse-renal cancer cells (Renca)-embedded mice.
- Fig. 15 is a diagram showing the degree of proliferation of CD4+ T cells and CD8+ T cells in blood and spleen after administration of recombinant vaccinia virus (OTS-412) and HU in mouse-breast cancer cells (4T1)-embedded mice. to be.
- Fig. 16 is a diagram showing the size of the left tumor after administration of the recombinant vaccinia virus (WR VV tk- ) and HU to the left tumor to a mouse-breast cancer cell (4T1)-embedded mouse.
- Fig. 17 is a diagram showing the size of the right tumor after administration of the recombinant vaccinia virus (WR VV tk- ) and HU to the left tumor to a mouse-breast cancer cell (4T1)-embedded mouse.
- Fig. 18 is a diagram illustrating the distribution of recombinant vaccinia virus in mouse tumor tissues on day 22 after administration of wild-type vaccinia virus (WR) and HU to mouse-renal cancer cells (Renca)-embedded mice.
- WR wild-type vaccinia virus
- Renca mouse-renal cancer cells
- FIG. 19 is a diagram illustrating the distribution of wild-type vaccinia virus in liver and kidney tissues after administration of wild-type vaccinia virus (WR) or wild-type vaccinia virus (WR) and HU to normal mice.
- Fig. 20 is a mouse-renal cancer cell (Renca)-embedded mouse with saline, HU, recombinant vaccinia virus (OTS-412), recombinant vaccinia virus and recombinant human granulocyte population stimulating factor (OTS-412+rh-G-CSF).
- OTS-412+rh-G-CSF human granulocyte population stimulating factor
- Figure 21 is a mouse-renal cancer cells (Renca)-after administration of saline, recombinant vaccinia virus or recombinant vaccinia virus (WR VV tk-) and HU to the implanted mice, the number of neutrophils in the blood of each group of mice was measured. It is a drawing.
- Figure 22 is a diagram of measuring the number of neutrophils in the blood of mice of each group after administration of saline, recombinant vaccinia virus or recombinant vaccinia virus (WOTS-418) and HU to mouse-renal cancer cells (Renca)-embedded mice to be.
- Fig. 23 is a diagram showing the number of neutrophils in the blood of mice of each group after administration of saline, lenalidomide, or HU to a mouse-renal cancer cell (Renca)-embedded mouse.
- Figure 24 is a mouse-renal cancer cell (Renca)-implanted mice administered saline, recombinant vaccinia virus, recombinant vaccinia virus (WOTS-418) and lenalidomide or recombinant vaccinia virus (WOTS-418) and HU After that, the number of neutrophils in the blood of mice in each group was measured.
- Renca mouse-renal cancer cell
- Fig. 25 is a diagram showing the size of a tumor of a mouse after administration of a recombinant vaccinia virus (WR VV tk -) and lenalidomide to a mouse-renal cancer cell (Renca)-embedded mouse.
- WR VV tk - recombinant vaccinia virus
- Renca mouse-renal cancer cell
- Fig. 26 is a diagram showing the size of a tumor of a mouse after administration of a recombinant vaccinia virus (WR VV tk -) and palbociclib to a mouse-renal cancer cell (Renca)-embedded mouse.
- WR VV tk - recombinant vaccinia virus
- Renca mouse-renal cancer cell
- Fig. 27 is a diagram showing the body weight of a mouse after administration of a recombinant vaccinia virus (WR VV tk -) and palbociclib to a mouse-renal cancer cell (Renca)-embedded mouse.
- WR VV tk - recombinant vaccinia virus
- Renca mouse-renal cancer cell
- FIG. 30 is a mouse-renal cancer cell-embedded mouse (Renca) after administration of an anti-cancer virus (Wyeth VV tk- ), a PD-L1 inhibitor, and HU, on days 0, 4, 10, 14, 17 and 21. In the figure, the size of the tumor was measured.
- Fig. 31 is a tumor on days 0, 3, 7, 10 and 14 after administration of an anticancer virus (WR VV tk- ), a CTLA-4 inhibitor and HU to a mouse-breast cancer cell-embedded mouse (4T1). It is a figure measuring the size of.
- an anticancer virus WR VV tk-
- CTLA-4 inhibitor a CTLA-4 inhibitor
- HU a mouse-breast cancer cell-embedded mouse
- FIG. 32 is a mouse-breast cancer cell-embedded mouse (4T1) after administration of an anti-cancer virus (WOTS-418), a PD-L1 inhibitor, and HU, on days 0, 3, 7, 10, 14, and 18. In the figure, the size of the tumor was measured.
- WOTS-418 anti-cancer virus
- a PD-L1 inhibitor a PD-L1 inhibitor
- Figure 33 is a mouse-renal cancer cell-implanted mouse (Renca) after administration of Western Reserve species vaccinia virus (WR), CTLA-4 inhibitor and HU, the size of the tumor was measured on days 0, 3 and 7 It is a drawing.
- One aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, comprising a vaccinia virus and an inhibitor of granule leukocyte formation as an active ingredient.
- the vaccinia virus and granule leukocyte formation inhibitor contained in the pharmaceutical composition may be administered simultaneously, sequentially, or in reverse order. Specifically, the vaccinia virus and granule leukocyte formation inhibitor may be administered at the same time. In addition, the granule leukocyte formation inhibitor may be administered first and then the vaccinia virus may be administered. Furthermore, the vaccinia virus may be administered first, and then the granule leukocyte formation inhibitor may be administered. In addition, the granule leukocyte formation inhibitor may be administered first, then the vaccinia virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the vaccinia virus is Western Reserve (WR), NYVAC (New York Vaccinia Virus), Wyeth (The New York City Board of Health; NYCBOH), LC16m8, Lister, Copenhagen, Tiantan ( Tian Tan), USSR, TashKent, Evans, IHD-J (International Health Division-J) or IHD-W (International Health Division-White) vaccinia virus strain, but limited thereto. It does not become.
- Western Reserve species vaccinia virus and Wyeth species vaccinia virus were used.
- the vaccinia virus may be a wild type vaccinia virus or a recombinant vaccinia virus.
- the recombinant vaccinia virus may have a wild-type vaccinia virus gene deleted or a foreign gene inserted therein.
- TK thymidine kinase
- VVF vaccinia growth factor
- WR53.5 F13.5L
- F14.5 A56R, B18R, or a combination thereof
- Genes related to virulence of a virus encoding any one selected from the group consisting of may be deleted.
- the inserted foreign genes are HSV-TK (Herpes simplex virus thymidine kinase), mutated HSV-TK, GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (Granulocyte colony-stimulating factor), CD (cytosin deaminase), carboxyl esterase (carboxyl esterase) type 1, carboxyl esterase type 2, INF- ⁇ (Interferone beta), somatostatin receptor 2 (somatostatin receptor 2), and any one selected from the group consisting of a combination thereof It may be a gene that promotes the encoding immunity.
- HSV-TK Herpes simplex virus thymidine kinase
- mutated HSV-TK GM-CSF (granulocyte-macrophage colony-stimulating factor)
- G-CSF Gramulocyte colony-stimulating factor
- CD cytosin deaminase
- carboxyl esterase
- the recombinant vaccinia virus is Western Reserve (WR), NYVAC (New York Vaccinia Virus), Wyeth (The New York City Board of Health; NYCBOH), LC16m8, Lister, Copenhagen , Tian Tan, USSR, TashKent, Evans, International Health Division-J (IHD-J) or International Health Division-White (IHD-W) vaccinia virus species TK of vaccinia virus
- the gene may have been deleted.
- a recombinant vaccinia virus in which the TK gene of Western Reserve species vaccinia virus was deleted was used, which was designated as "WR VV tk-”.
- a recombinant vaccinia virus in which the TK gene of the Wyeth species vaccinia virus was deleted was used, which was designated as "Wyeth VV tk-".
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species TK gene and VGF gene of vaccinia virus. May have come to fruition.
- a recombinant vaccinia virus in which the TK gene and VGF gene of Western Reserve species vaccinia virus were deleted was used, and this was designated as "VV_DD".
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted, and , HSV-TK gene may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted.
- the mutated HSV-TK gene may be inserted.
- a recombinant vaccinia virus in which the TK gene of the Wyeth species vaccinia virus was deleted and the gene encoding the HSV-TK fragment (1-330 aa) of SEQ ID NO: 1 was inserted at the position was used. , It was named "OTS-412".
- a recombinant vaccinia virus in which the TK gene of Western Reserve species vaccinia virus is deleted, and a gene encoding the HSV-TK variant of SEQ ID NO: 2 of the HSV-TK gene is inserted at that position. was used, and it was named "WOTS-418".
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted, and , GM-CSF gene may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted.
- G-CSF gene may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted.
- CD (Cytosine deaminiase) gene may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted.
- Somatostatin receptor 2 gene may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species
- the TK gene of vaccinia virus is deleted.
- HSV-TK Herpes simplex virus thymidine kinase
- mutated HSV-TK GM-CSF (granulocyte-macrophage colony-stimulating factor), G-CSF (Granulocyte colony-stimulating factor), CD (cytosin deaminase) or somatostatin receptor Any two or more genes selected from the group consisting of genes encoding 2 (somatostatin receptor 2) may be inserted.
- the recombinant vaccinia virus is Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus species TK gene and VGF gene of vaccinia virus.
- HSV-TK Herpes simplex virus thymidine kinase
- mutated HSV-TK GM-CSF (granulocyte-macrophage colony-stimulating factor)
- G-CSF Granulocyte colony-stimulating factor
- CD cytosin deaminase
- any one gene selected from the group consisting of a gene encoding somatostatin receptor 2 and a combination thereof may be inserted.
- gene deletion used in the present invention means that a gene is partially deleted, all of a gene is deleted, or a foreign gene is inserted into the gene so that the gene is not expressed. When a part of the gene is deleted, some amino acids at the N-terminus or C-terminus of the expressed polypeptide may be deleted.
- TK thymidine kinase
- the term "TK (thymidine kinase)" used in the present invention is called thymidine kinase, and refers to an enzyme involved in the biosynthesis of nucleotides.
- the TK is an enzyme used for both cell and viral nucleotide biosynthesis.
- normal cells no longer divide, so TK does not exist, and even cells that divide rapidly like hair follicle cells do not have enough TK to be used by the virus. Taking advantage of this, by deleting the TK gene in the virus, the virus can proliferate only when the TK of the cancer cell is present, so that only cancer cells can be selectively killed.
- VGF vaccinia growth factor
- GM-CSF used in the present invention is a granulocyte-macrophage colony-stimulating factor that is secreted by macrophages, T cells, mast cells, natural killer cells, endothelial cells and fibroblasts. It means the protein that becomes. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, basophils, eosinophils) and monocytes. In addition, GM-CSF induces an immune response by rapidly increasing the number of macrophages.
- the GM-CSF may be derived from human and may be a protein having the sequence of GenBank: AAA52578.1.
- CD used in the present invention is called cytosine deaminase, and refers to an enzyme that hydrolyzes cytosine to contact a reaction between uracil and ammonia.
- G-CSF used in the present invention is a granulocyte colony-stimulating factor, which is a cytokine produced by macrophages, fibroblasts, endothelial cells, etc. by stimulation by inflammation or endotoxin. Means.
- the G-CSF promotes the production of neutrophils.
- the G-CSF may be derived from human (rhGCSF), and may be a protein having a sequence of GenBank: AAA03056.1.
- somatostatin receptor 2 used in the present invention means a protein encoded by the SSTR2 gene in humans.
- the somatostatin receptor 2 is mainly expressed in tumors, and neuroendocrine tumor patients overexpressing somatostatin receptor 2 show an improved prognosis.
- Somatostatin receptor 2 has the ability to stimulate apoptosis in many cells, including cancer cells.
- the myeloid cells may be granular leukocytes, and specifically, the myeloid cells may be neutrophils, eosinophils, or basophils.
- the granule leukocyte formation inhibitor may be a substance that inhibits granular leukocytes, such as neutrophils, eosinophils, or basophils, which are mainly produced in the bone marrow.
- the granule leukocyte formation inhibitor may be referred to as or include a neutrophil inhibitor when reducing or inhibiting the number of neutrophils, which is one of myeloid cells, in the body.
- the neutrophils are also called heavy neutrophils, and refer to circulating neutrophils, which are a kind of granular leukocytes (granulocytes) mainly made in the bone marrow.
- Neutrophils are the main component of granular leukocytes, and the normal number is about 1,500 to 8,000 in 1 mm 3 of blood. Neutrophils absorb foreign substances such as bacteria that invade the body through phagocytosis and decompose them with digestive enzymes such as hydrogen peroxide and lysosomes.
- absolute neutrophil count means the number of white blood cells multiplied by the neutrophil percentage.
- the granule leukocyte formation inhibitors include hydroxyurea, lenalidomide, thalidomide, tadalafil, palbociclib, alkylating agents, anthracyclines, Metabolic antagonists (Antimetabolites), camptothecins (Camptothecins), epipodophyllotoxins (Epipodophyllotoxins), mitomycin C (Mitomycin C), Taxane (Taxanes) or vinblastine (Vinblastine) may be.
- the hydroxyurea may be a compound having the following formula (1).
- the hydroxyurea may be included in the pharmaceutical composition in the form of a commercialized drug containing hydroxyurea.
- the commercialized drug containing the hydroxyurea component may be Hydroxyurea®, Hydrea®, DroxiaTM, MylocelTM, Siklos® hydrin capsule, but is not limited thereto.
- the hydroxyurea can be taken orally, and parenteral administration is also possible.
- the lenalidomide may be a compound having the following formula (2).
- the lenalidomide is an anticancer agent used for the treatment of multiple myeloma and the like.
- the lenalidomide stops the growth cycle of cells and inhibits cancer growth by activating a tumor suppressor gene as an anti-tumor effect.
- tumor cells are removed by activating immune cells such as T cells, NK cells (natural killer cells), and B cells.
- angiogenesis inhibitory effect that suppresses the formation of new blood vessels to supply nutrients to cancer cells.
- the thalidomide may be a compound having the following formula (3).
- thalidomide Although the exact mechanism of thalidomide is not known, it is used for the treatment of multiple myeloma and severe skin lesions in patients with leprosy (Hansen's disease).
- the tadalafil may be a compound having the following formula (4).
- the palbosil clip may be a compound having the following formula (5).
- the alkylating agent may be a nitrogen mustard, an ethylene derivative, an alkyl sulfonic acid derivative, a nitrosorea or a triazene compound among chemotherapeutic drugs targeting malignant tumors. These can also be referred to as alkylating agents because they replace hydrogen in many organic compounds, proteins or nucleic acids with alkyl groups.
- the alkylation by the alkylating agent inhibits DNA replication of tumor cells and transcription of mRNA, and may exhibit anti-tumor activity. As a common pharmacological action, it acts non-specifically on each phase of the cell cycle, and can prevent cell division with high proliferation. Since it exhibits a similar action to radiation, hematopoietic disorders are strong and can cause immunosuppression.
- the anthracycline is a drug used in cancer chemotherapy extracted from Streptomyces bacteria and is used to treat many cancers including leukemia, lymphoma, breast cancer, stomach cancer, uterine cancer, ovarian cancer, bladder cancer and lung cancer.
- the first anthracycline discovered was Daunorubicin (trade name: Daunomycin), which was naturally produced by Streptomyces peucetius, a species of actinomycetes.
- Clinically most important anthracyclines include doxorubicin, daunorubicin, epirubicin, and idarubicin.
- the metabolic antagonist may be a substance that inhibits cell growth and proliferation by antagonizing essential metabolites indispensable to the metabolism or growth of microorganisms or tumor cells.
- Slupamine which is used as a chemotherapy drug and historically antagonizes the bacterial paraaminobenzoic acid PABA, was first produced.
- the metabolic antagonists are sulfa drugs for bacteria, purine metabolic antagonists for malignant tumors (8-azaguanine, 6-thioguanine, 6-mercaptopurine), pilimi metabolic antagonists (5-fluorouracil, cytarabine). , Azaurizin), folic acid metabolism antagonist (4-aminopterin, methotrexet) or glutamine metabolism antagonist (azerin, DON).
- the camptothecin may be a natural anticancer substance isolated from plants such as Camptotheca acuminata (Camptotheca, Happy tree) Chonemorpha fragrans.
- the camptothecin may be a compound having the following formula (6).
- the epipodophyllotoxin may be a natural anticancer substance naturally produced in the root of Podophyllum peltatum.
- the derivatives of epipodophyllotoxin can be used for cancer treatment at present.
- the epipodophyllotoxin may be a compound having the following formula (7).
- the mitomycin C may be an antibiotic isolated by Streptomyces griseus.
- the mitomycin C is stable to heat, has the lowest toxicity and strong anticancer effect.
- the mitomycin C can inhibit the proliferation of malignant tumor cells by inhibiting the cell nucleus division by inhibiting the cell enzyme system and nucleic acid metabolism.
- Side effects of mitomycin C include leukocyte reduction and bleeding accompanied by platelet reduction.
- the taxane is also referred to as a cell division inhibitor or an antimicrotubule inhibitor, and may be an anticancer agent that inhibits the growth of cancer cells by inhibiting cell division.
- the taxane can kill cancer cells by interfering with microtubules through which chromosomes move during cell mitosis.
- the taxane is used for the treatment of various types of cancer such as breast cancer, ovarian cancer, and non-small cell lung cancer.
- the taxene includes paclitaxel, docetaxel, and the like.
- the vinblastine may be an anticancer agent of a vinca alkaloid component used in the treatment of various types of cancer.
- the vinblacitin is a substance extracted for the first time from the periwinkle plant belonging to the family Oleander, and a synthesized substance is currently used.
- the vinblastine is the most widely used agent among anticancer agents, and is also widely used as a combination therapy with other anticancer agents.
- the vinblastine prevents the division of cancer cells by interfering with the normal function of the microtubules. It can be widely used for testicular cancer, breast cancer, lymphoma, and Kaposi's sarcoma.
- the most important side effects of vinblastine are reduction of white blood cells and platelets, and gastrointestinal disorders, increased blood pressure, excessive sweating, depression, muscle pain, nausea, headache, and the like may appear as side effects.
- the dosage of the vaccinia virus depends on the condition and weight of the individual, the degree of the disease, the form of the drug, the route and duration of administration, and may be appropriately selected by a person skilled in the art.
- the patient may be administered 1 ⁇ 10 5 to 1 ⁇ 10 18 virus particles, a viral unit having infectivity (TCID50), or a plaque-forming unit (pfu) of vaccinia virus.
- TCID50 viral unit having infectivity
- pfu plaque-forming unit
- the vaccinia virus may be administered at a dose of 1 ⁇ 10 5 to 1 ⁇ 10 10 pfu. More preferably, the vaccinia virus may be administered at a dose of 1 ⁇ 10 5 or more and less than 1 ⁇ 10 9 pfu. In one embodiment of the present invention, the vaccinia virus was administered at 1 ⁇ 10 5 or 1 ⁇ 10 7 pfu.
- the granule leukocyte formation inhibitor may be administered at a dose of 1 mg/kg/day to 100 mg/kg/day or 10 mg/kg/day to 90 mg/kg/day.
- the dosage of the granule leukocyte formation inhibitor is 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/day. It can be administered at a rate of kg/day, 25 mg/kg/day to 65 mg/kg/day, or 30 mg/kg/day to 60 mg/kg/day.
- hydroxyurea, lenalidomide, and palbociclib as granule leukocyte formation inhibitors are 25 mg/kg/day, 30 mg/kg/day, 50 mg/kg/day, 60 mg/ It was administered at kg/day or 100 mg/kg/day.
- it can be administered several times a day. Specifically, it may be administered once to 4 times a day, or once to 2 times a day.
- the pharmaceutical composition may additionally include an immune checkpoint inhibitor (ICI).
- ICI immune checkpoint inhibitor
- the immune checkpoint inhibitor refers to a substance that inhibits the mechanism of cancer cells that interfere with the activation of T cells, and anti-PD-L1 antibody, anti-PD-1 antibody, anti-CTLA4 antibody, anti PD-L2 antibody, LTF2 regulation Antibody, anti-LAG3 antibody, anti-A2aR antibody, anti-TIGIT antibody, anti-TIM-3 antibody, anti-B7-H3 antibody, anti-B7-H4 antibody, anti-VISTA antibody, anti-CD47 antibody, anti- It may be any one selected from the group consisting of a BTLA antibody, an anti-KIR antibody, an anti-IDO antibody, and a combination thereof.
- Cancer cells are a mechanism to evade the immune response, hijacking the immune checkpoint system.
- cancer cells use immune checkpoint receptors to avoid immune responses, and representative receptors include PD-L1, PD-1, and CTLA-4.
- an immune checkpoint inhibitor a molecule that specifically binds to an immune checkpoint receptor, is used for cancer treatment.
- the first immune checkpoint inhibitor is ipilimumab (Yervoy®), a monoclonal antibody that specifically binds to CTLA-4 (cytotoxic T-lymphocyte associated antigen-4).
- the next developed immune checkpoint treatments are monoclonal antibodies against PD-1 (programmed cell death-1) and the corresponding ligand PD-L1 (programmed death ligand-1).
- Representative drugs include anti-PD-1 antibodies such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), and the like, and anti-PD-L1 antibodies, avelumab (avelumab, Bavencio®), Ate Zolizumab (Tecentriq®) and durvalumab (Imfinzi®).
- GITR glucocorticoid-induced TNFR-related protein
- KIR killer cell immunooglobulin-like receptor
- LAG-3 lymphocyte-activation gene-3
- TIM-3 T-cell immunoglobulin and mucin-domain containing-3)
- Tumor-necrosis factor receptor superfamily member 4 TNFRSF4
- the dosage of the immune checkpoint inhibitor may be administered in accordance with the dosage and administration of each manufacturer.
- the dosage of the immune checkpoint inhibitor may be 0.1 mg/kg to 10 mg/kg, and 1 mg/kg to 5 mg/kg.
- 3 mg/kg is injected intravenously over 60 minutes at intervals of 2 weeks, and the dosage and administration as a combination therapy are 1 mg. /Kg can be instilled intravenously over 30 minutes.
- 200 mg may be injected intravenously over 30 minutes at intervals of 3 weeks.
- the dosage and administration are different depending on the product, so it is desirable to administer it according to the manufacturer's dosage and administration.
- the pharmaceutical composition additionally includes an immune checkpoint inhibitor
- the anticancer virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor included in the pharmaceutical composition may be administered simultaneously, sequentially, or in reverse order.
- the anticancer virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor may be administered at the same time.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor may be administered, and then an anticancer virus may be administered.
- the granule leukocyte formation inhibitor may be administered first, and then the anticancer virus may be administered, and then the immune checkpoint inhibitor may be administered.
- the granule leukocyte formation inhibitor may be administered first, and the anticancer virus and the immune checkpoint inhibitor may be administered simultaneously.
- the anticancer virus may be administered first, the granule leukocyte formation inhibitor may be administered, and then an immune checkpoint inhibitor may be administered.
- the anticancer virus may be administered first, the immune checkpoint inhibitor may be administered, and then the granule leukocyte formation inhibitor may be administered.
- the anticancer virus may be administered first, and the granule leukocyte formation inhibitor and the immune checkpoint inhibitor may be administered simultaneously.
- the immune checkpoint inhibitor may be administered first, the granule leukocyte formation inhibitor may be administered, and then the anticancer virus may be administered.
- the immune checkpoint inhibitor may be administered first, the anticancer virus may be administered, and then the granule leukocyte formation inhibitor may be administered.
- the immune checkpoint inhibitor may be administered first, and then the anticancer virus and granule leukocyte formation inhibitor may be administered simultaneously.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, the immune checkpoint inhibitor may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor is administered, the anticancer virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be first administered, and the anticancer virus and the immune checkpoint inhibitor may be simultaneously administered, and then the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, then the granule leukocyte formation inhibitor may be administered again, and the immune checkpoint inhibitor may be administered.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor is administered, then the granule leukocyte formation inhibitor may be administered again, and the anticancer virus may be administered.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, the granule leukocyte formation inhibitor is administered again, the immune checkpoint inhibitor is administered, and the granule leukocyte formation inhibitor may be administered again.
- the hydroxyurea may be administered first, the immune checkpoint inhibitor is administered, the granulocyte formation inhibitor is administered again, the anticancer virus is administered, and the granule leukocyte formation inhibitor is administered again.
- the anticancer virus may be administered first, the granule leukocyte formation inhibitor is administered, an immune checkpoint inhibitor is administered, and then the granule leukocyte formation inhibitor may be administered again.
- the immune checkpoint inhibitor may be administered first, the granule leukocyte formation inhibitor may be administered, an anticancer virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the cancer may be solid cancer or blood cancer.
- the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma.
- the solid cancer is lung cancer, colon cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymus cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer and its It may be any one selected from the group consisting of a combination.
- the pharmaceutical composition of the present invention may further include a physiologically acceptable carrier.
- the pharmaceutical composition of the present invention may further include suitable excipients and diluents commonly used in the preparation of pharmaceutical compositions.
- it may be formulated and used in the form of an injection according to a conventional method.
- the pharmaceutical composition may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a freeze-dried preparation, a suppository, etc. as a preparation for parenteral administration.
- a non-aqueous solvent and suspension propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like may be used.
- a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogelatin, and the like may be used.
- the route of administration, dosage, and frequency of administration of the pharmaceutical composition may be administered to the subject in various ways and amounts depending on the condition of the patient and the presence or absence of side effects, and the optimal administration method, dosage, and frequency of administration are appropriate for those skilled in the art. You can choose from a range.
- the pharmaceutical composition may be administered in combination with other drugs or physiologically active substances known to have a therapeutic effect on the disease to be treated, or may be formulated in the form of a combination formulation with other drugs.
- the pharmaceutical composition may be administered parenterally, intratumoral, intraperitoneal, sub-cutaneous, intra-dermal, intra-nodal, intra-arterial and intravenous It can be administered by a suitable method, such as intra-venous. Preferably, it may be intratumoral, intraperitoneal or intravenous administration. Meanwhile, the dosage of the pharmaceutical composition may be determined according to an administration schedule, dosage, and health status of a patient.
- the pharmaceutical composition for cancer treatment may be characterized in that the cancer selectivity of the vaccinia virus is increased.
- kits for preventing or treating cancer comprising a first composition comprising a vaccinia virus as an active ingredient and a second composition comprising a granule leukocyte formation inhibitor as an active ingredient.
- the kit may additionally include a third composition comprising an immune checkpoint inhibitor as an active ingredient.
- the vaccinia virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor are as described above in the pharmaceutical composition.
- the second composition comprising the granule leukocyte formation inhibitor as an active ingredient may be a commercialized drug.
- commercialized drugs containing hydroxyurea as an active ingredient may be Hydroxyurea ® , Hydrea ® , Droxia TM , Mylocel TM , and Siklos ® hydrin capsules.
- the second composition can be taken orally, and parenteral administration is also possible.
- the dosage of the first composition varies depending on the condition and weight of the individual, the degree of disease, the form of the drug, the route and duration of administration, and may be appropriately selected by those skilled in the art.
- the patient may be administered 1 ⁇ 10 5 to 1 ⁇ 10 18 virus particles, a viral unit having infectivity (TCID50), or a plaque-forming unit (pfu) of vaccinia virus.
- the first composition may be administered in a dose of 1 ⁇ 10 5 to 1 ⁇ 10 10 pfu. More preferably, the first composition may be administered in a dose of 1 ⁇ 10 5 to 1 ⁇ 10 9 pfu or less. In one embodiment of the present invention, the first composition was administered at 1 ⁇ 10 5 or 1 ⁇ 10 7 pfu.
- the dosage of the second composition may be administered in a dose of 1 mg/kg/day to 100 mg/kg/day or 10 mg/kg/day to 90 mg/kg/day.
- the dosage of the second composition is 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/kg /day, 25 mg/kg/day to 65 mg/kg/day or 30 mg/kg/day to 60 mg/kg/day.
- the second composition was administered at 25 mg/kg/day, 30 mg/kg/day, 50 mg/kg/day, 60 mg/kg/day or 100 mg/kg/day. .
- it can be administered several times a day. Specifically, it may be administered once to 4 times a day, or once to 2 times a day.
- the dosage of the third composition may be administered in accordance with the usage and dosage of each manufacturer of the immune checkpoint inhibitor contained in the third composition.
- the dosage of the third composition may be 0.1 mg/kg to 10 mg/kg, and 1 mg/kg to 5 mg/kg.
- the cancer may be solid cancer or blood cancer.
- the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma.
- the solid cancer is lung cancer, colon cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymus cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer and its It may be any one selected from the group consisting of a combination.
- the first composition, the second composition, and the third composition may further include a physiologically acceptable carrier.
- the composition included in the kit of the present invention may further include suitable excipients and diluents commonly used in the preparation of pharmaceutical compositions.
- it may be formulated and used in the form of an injection according to a conventional method.
- the first composition, the second composition, and the third composition are preparations for parenteral administration and may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
- aqueous solutions may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
- non-aqueous solvent and suspension propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like may be used.
- As a base for suppositories witepsol, macrogol, tween61, cacao butter, laurin, glycerogelatin, and the like may be used.
- the route of administration, dosage, and frequency of administration of the first composition, the second composition, and the third composition can be administered to the subject in various methods and amounts depending on the condition of the patient and the presence or absence of side effects, and the optimal administration method and dosage And the frequency of administration can be selected in an appropriate range by a person skilled in the art.
- the pharmaceutical composition may be administered in combination with other drugs or physiologically active substances known to have a therapeutic effect on the disease to be treated, or may be formulated in the form of a combination formulation with other drugs.
- the second composition may be administered orally or parenterally. Specifically, the second composition may be administered parenterally, and may be administered intraperitoneal, intraarterial, or intra-venous.
- the first composition may be administered parenterally, intratumoral, intraperitoneal, sub-cutaneous, intra-dermal, intra-nodal, intra-arterial and It can be administered by a suitable method, such as intra-venous. Preferably, it may be intratumoral, intraperitoneal or intravenous administration. Meanwhile, the dosage of the first composition and the second composition may be determined according to an administration schedule, dosage, and health status of the patient.
- the first composition may be administered once to 10 times or 2 to 5 times, and may be administered to an individual at intervals of 7 to 30 days. Specifically, the first composition may be administered at intervals of 7 days, 14 days, 21 days or 30 days.
- the second composition may be administered before or after administration of the first composition.
- the second composition may be continuously administered once a day from 3 to 5 days before administration of the first composition, and within 24 hours or 24 hours after administration of the first composition, continuously for 9 to 28 days. It can be administered once a day.
- the first composition was administered continuously once a day from 1 to 3 days before administration
- the second composition was 1 for 13 days, 17 days, 18 days or 28 days after administration of the first composition. It was administered once a day.
- the third upper limb composition may be continuously administered for at least once a week, 1 week to 10 weeks after administration of the first composition. Specifically, the third composition may be continuously administered for 1 to 8 weeks at least twice a week after administration of the first composition.
- Another aspect of the present invention provides a method of treating cancer comprising administering a vaccinia virus and an inhibitor of granulocyte formation to an individual suffering from cancer.
- the treatment method may further include administering an immune checkpoint inhibitor to the individual with cancer.
- the anticancer virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor are the same as described above in the pharmaceutical composition.
- the vaccinia virus may be Western Reserve, NYVAC, Wyeth, LC16m8, Lister, Copenhagen, Tiantan, USSR, Tashkent, Evans, IHD-J or IHD-W vaccinia virus strain, but is not limited thereto. .
- the vaccinia virus and granule leukocyte formation inhibitor may be administered simultaneously, sequentially, or in reverse order. Specifically, the vaccinia virus and granule leukocyte formation inhibitor may be administered at the same time. In addition, the granule leukocyte formation inhibitor may be administered first and then the vaccinia virus may be administered. Furthermore, the vaccinia virus may be administered first, and then the granule leukocyte formation inhibitor may be administered. In addition, the granule leukocyte formation inhibitor may be administered first, then the vaccinia virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the anticancer virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor may be administered simultaneously, sequentially, or in reverse order.
- the anticancer virus, granule leukocyte formation inhibitor, and immune checkpoint inhibitor may be administered at the same time.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor may be administered, and then an anticancer virus may be administered.
- the granule leukocyte formation inhibitor may be administered first, and then the anticancer virus may be administered, and then the immune checkpoint inhibitor may be administered.
- the granule leukocyte formation inhibitor may be administered first, and the anticancer virus and the immune checkpoint inhibitor may be administered simultaneously.
- the anticancer virus may be administered first, the granule leukocyte formation inhibitor may be administered, and then an immune checkpoint inhibitor may be administered.
- the anticancer virus may be administered first, the immune checkpoint inhibitor may be administered, and then the granule leukocyte formation inhibitor may be administered.
- the anticancer virus may be administered first, and the granule leukocyte formation inhibitor and the immune checkpoint inhibitor may be administered simultaneously.
- the immune checkpoint inhibitor may be administered first, the granule leukocyte formation inhibitor may be administered, and then the anticancer virus may be administered.
- the immune checkpoint inhibitor may be administered first, the anticancer virus may be administered, and then the granule leukocyte formation inhibitor may be administered.
- the immune checkpoint inhibitor may be administered first, and then the anticancer virus and granule leukocyte formation inhibitor may be administered simultaneously.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, the immune checkpoint inhibitor may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor is administered, the anticancer virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be first administered, and the anticancer virus and the immune checkpoint inhibitor may be simultaneously administered, and then the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, then the granule leukocyte formation inhibitor may be administered again, and the immune checkpoint inhibitor may be administered.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor is administered, then the granule leukocyte formation inhibitor may be administered again, and the anticancer virus may be administered.
- the granule leukocyte formation inhibitor may be administered first, the anticancer virus is administered, the granule leukocyte formation inhibitor is administered again, the immune checkpoint inhibitor is administered, and the granule leukocyte formation inhibitor may be administered again.
- the granule leukocyte formation inhibitor may be administered first, the immune checkpoint inhibitor is administered, the granule leukocyte formation inhibitor is administered again, the anticancer virus is administered, and then the granule leukocyte formation inhibitor may be administered again.
- the anticancer virus may be administered first, the granule leukocyte formation inhibitor is administered, an immune checkpoint inhibitor is administered, and then the granule leukocyte formation inhibitor may be administered again.
- the immune checkpoint inhibitor may be administered first, the granule leukocyte formation inhibitor may be administered, an anticancer virus may be administered, and the granule leukocyte formation inhibitor may be administered again.
- the dosage of the vaccinia virus depends on the condition and weight of the individual, the degree of the disease, the form of the drug, the route and duration of administration, and may be appropriately selected by a person skilled in the art.
- the patient may be administered 1 ⁇ 10 5 to 1 ⁇ 10 18 virus particles, a viral unit having infectivity (TCID50), or a plaque-forming unit (pfu) of vaccinia virus.
- TCID50 viral unit having infectivity
- pfu plaque-forming unit
- the vaccinia virus may be administered at a dose of 1 ⁇ 10 5 to 1 ⁇ 10 10 pfu. More preferably, the vaccinia virus may be administered at a dose of 1 ⁇ 10 5 or more and less than 1 ⁇ 10 9 pfu. In one embodiment of the present invention, the vaccinia virus was administered at 1 ⁇ 10 5 or 1 ⁇ 10 7 pfu.
- the granule leukocyte formation inhibitor may be administered at a dose of 1 mg/kg/day to 100 mg/kg/day or 10 mg/kg/day to 90 mg/kg/day.
- the dosage of the granule leukocyte formation inhibitor is 10 mg/kg/day to 90 mg/kg/day, 15 mg/kg/day to 80 mg/kg/day, 20 mg/kg/day to 70 mg/day. It can be administered at a rate of kg/day, 25 mg/kg/day to 65 mg/kg/day, or 30 mg/kg/day to 60 mg/kg/day.
- hydroxyurea, lenalidomide, and palbociclib as granule leukocyte formation inhibitors are 25 mg/kg/day, 30 mg/kg/day, 50 mg/kg/day, 60 mg/ It was administered at kg/day or 100 mg/kg/day.
- it can be administered several times a day. Specifically, it may be administered once to 4 times a day, or once to 2 times a day.
- the vaccinia virus may be administered once to 10 times or 2 to 5 times, and may be administered to an individual at intervals of 7 to 30 days. Specifically, the vaccinia virus may be administered at intervals of 7 days, 14 days, 21 days or 30 days.
- the granule leukocyte formation inhibitor may be administered before, during or after vaccinia virus administration. Specifically, the granule leukocyte formation inhibitor may be administered before or after vaccinia virus is administered. The granule leukocyte formation inhibitor may be continuously administered once a day from 3 to 5 days before vaccinia virus administration, and from 24 hours after vaccinia virus administration, the granular leukocyte formation inhibitor may be continuously administered once a day for 9 to 28 days. I can. In one embodiment of the present invention, the granule leukocyte formation inhibitor was continuously administered once a day from 1 to 3 days before vaccinia virus administration, and for 13, 17, 18, or 28 days after vaccinia virus administration. It was administered once a day.
- the cancer may be solid cancer or blood cancer.
- the blood cancer may be any one selected from the group consisting of lymphoma, acute leukemia, and multiple myeloma.
- the solid cancer is lung cancer, colon cancer, prostate cancer, thyroid cancer, breast cancer, brain cancer, head and neck cancer, esophageal cancer, skin cancer, thymus cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, rectal cancer, gallbladder cancer, biliary tract cancer, pancreatic cancer and its It may be any one selected from the group consisting of a combination.
- the granule leukocyte formation inhibitor may be administered orally or parenterally. Specifically, the granule leukocyte formation inhibitor may be administered parenterally, and may be administered intraperitoneal, intraarterial, or intra-venous.
- the vaccinia virus and granulocyte formation inhibitor may be administered parenterally, intratumoral, intraperitoneal, sub-cutaneous, intra-dermal, intra-nodal ), intra-arterial and intravenous (intra-venous), etc. may be administered by a suitable method. Preferably, it may be intratumoral, intraperitoneal or intravenous administration. Meanwhile, the dose of the vaccinia virus and the granule leukocyte formation inhibitor may be determined according to an administration schedule, a dose, and a patient's health status.
- subject used in the present invention refers to a person suffering from cancer or a condition in which a disease can be alleviated, suppressed, or treated by administering the pharmaceutical composition of the present invention.
- administration means introducing an effective amount of a substance into an individual by an appropriate method, and the route of administration of the vaccinia virus and granulocyte formation inhibitor is through a general route that can reach the target tissue. Can be administered.
- the vaccinia virus and granule leukocyte formation inhibitor may be administered in combination with other drugs or physiologically active substances known to have a therapeutic effect on the disease to be treated, or may be formulated in the form of a combination formulation with other drugs.
- Another aspect of the present invention provides the use of a composition comprising a vaccinia virus and an inhibitor of granulocyte formation for preventing or treating cancer.
- Another aspect of the present invention provides the use of a composition comprising a vaccinia virus and an inhibitor of granule leukocyte formation for preparing a medicament for preventing or treating cancer.
- an anticancer adjuvant comprising an inhibitor of granule leukocyte formation as an active ingredient.
- the granule leukocyte formation inhibitor is the same as described above in the pharmaceutical composition.
- the anticancer adjuvant may be used as an anticancer adjuvant for an anticancer agent containing vaccinia virus as an active ingredient.
- the anticancer adjuvant may be characterized by improving, enhancing or increasing the anticancer activity of vaccinia virus.
- the anticancer adjuvant may be characterized by increasing the cancer selectivity of vaccinia virus.
- the granule leukocyte formation inhibitors include hydroxyurea, lenalidomide, thalidomide, tadalafil, palbociclib, alkylating agents, anthracyclines, Metabolic antagonists (Antimetabolites), camptothecins (Camptothecins), epipodophyllotoxins (Epipodophyllotoxins), mitomycin C (Mitomycin C), Taxane (Taxanes) or vinblastine (Vinblastine) may be.
- TK thymidine kinase
- Wyeth species NYC Department of Health
- Western Reserve species were purchased from the American Type Culture Collection (ATCC).
- ATCC American Type Culture Collection
- the TK site of the wild-type vaccinia virus was replaced with a shuttle plasmid having a firefly luciferase reporter (p7.5 promoter) gene or a shuttle plasmid having a GFP gene using a vector.
- Hela cells In order to secure the recombinant virus, Hela cells (ATCC) were cultured in EMEM medium containing 4 ⁇ 10 5 cells/well conditions and 10% fetal calf serum in a 6-well plate. Then, the wild-type vaccinia virus was treated with 0.05 MOI, and after 2 hours, it was replaced with an EMEM medium containing 2% fetal calf serum. Thereafter, 4 ⁇ g of the linearized shuttle plasmid vector prepared in Preparation Example 1.1 was transfected using XfectTM polymer (Clonetech 631317, USA). After culturing for 4 hours, the cells were replaced with EMEM medium containing 2% fetal calf serum, and then cultured for an additional 72 hours.
- sucrose cushion method sucrose cushion method
- TK thymidine kinase
- HSV-TK mutated thymidine kinase
- TK thymidine kinase
- HSV-TK mutated thymidine kinase
- the TK site of the Western Reserve species wild-type vaccinia virus contains an enhanced green fluorescent protein (EGFP) gene.
- EGFP enhanced green fluorescent protein
- mice female, 10 weeks sold in Orient Bio (Busan) were implanted with a Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after an adaptation period of 2 days. After observing until the tumor size reached 50 mm 3 to 80 mm 3 , administration of wild-type vaccinia virus was started.
- Renca cancer cell line Renca cancer cell line
- Western Reserve species wild-type vaccinia virus WR
- a group receiving saline intraperitoneally was set as a negative control group, and a group receiving wild-type vaccinia virus (WR, 1 ⁇ 10 5 pfu) was set as a positive control group.
- a group receiving a combination administration of wild-type vaccinia virus (WR, 1 ⁇ 10 5 pfu) and hydroxyurea (30 mg/kg) was set as an experimental group. Wild-type vaccinia virus was administered once intratumorally, and hydroxyurea was administered intraperitoneally 5 times/week, excluding the day of administration of wild-type vaccinia virus, from 1 day before wild-type vaccinia virus administration to 14 days after administration.
- mice were measured on the 3rd, 7th, 10th and 14th days after administration of each drug to the negative control group, the positive control group, and the experimental group of Experimental Example 1.1. As a result, significant weight loss did not appear in all three groups (FIG. 2).
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus was started. On the other hand, the Western Reserve species-derived recombinant vaccinia virus (WR VV tk- ) has a stronger proliferative power in an allograft model than the Wyeth species-derived recombinant vaccinia virus.
- WR VV tk- Western Reserve species-derived recombinant vaccinia virus
- a group receiving saline intraperitoneally was set as a negative control group, and a group receiving recombinant vaccinia virus (WR VV tk- , 1 ⁇ 10 7 pfu) was set as a positive control group.
- the group receiving the combination administration of the recombinant vaccinia virus and hydroxyurea was set as the experimental group.
- Recombinant vaccinia virus was administered intraperitoneally twice, and hydroxyurea was administered intraperitoneally 6 times/week, excluding the day of administration of the recombinant vaccinia virus from 1 day before administration to 21 days after administration of the recombinant vaccinia virus.
- tumor sizes were measured on the 0th, 3rd, 7th, 10th, 14th, 17th and 21st days. As a result, it was confirmed that the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 3).
- mice female, 10 weeks sold in Orient Bio (Busan) were subjected to an adaptation period of 2 days, and then a Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells was placed on the left thigh. I was avoided. After observing until the tumor size reached 50 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus was started.
- Renca cancer cell line Korea Cell Line Bank
- a group receiving saline intraperitoneally was set as a negative control group, and a group receiving recombinant vaccinia virus (WR VV tk- , 1 ⁇ 10 5 pfu) was set as a positive control group.
- the group receiving the combined administration of the recombinant vaccinia virus and hydroxyurea (30 mg/kg) was set as the experimental group.
- Recombinant vaccinia virus was administered once intratumorally, and hydroxyurea was administered intraperitoneally 6 times/week excluding the day of administration of the recombinant vaccinia virus from 1 day before administration to 14 days after administration of the recombinant vaccinia virus.
- tumor sizes were measured on the 0th, 3rd, 7th, 10th and 14th days. As a result, it was confirmed that the tumor size of the mice in the experimental group was inhibited by about 25% of the tumor size of the mice in the positive control group (FIG. 4).
- VV_DD recombinant vaccinia virus
- Recombinant vaccinia virus was administered intraperitoneally on days O and 5, and hydroxyurea was administered intraperitoneally 6 times/week from 1 day before administration to 15 days after administration of recombinant vaccinia virus except the day of administration of recombinant vaccinia virus. was administered.
- the size of the tumor was measured 1 day before administration of the drug to the mice in each group, 4 days and 7 days after administration. As a result, it was confirmed that the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 5). Through this, it was confirmed that a synergistic effect appears when the recombinant vaccinia virus (VV_DD) and hydroxyurea are co-administered.
- mice Female, 7 weeks sold in Orient Bio (Busan) were subjected to an adaptation period of 2 days, followed by a 5 ⁇ 10 6 cell number of NCI-H460 human lung cancer cancer cell line (Korean cell line). Ginkgo) was subcutaneously xenografted. After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus (WOTS-418) was started. On the other hand, Western Reserve species-derived recombinant vaccinia virus (WOTS-418) can be proliferated in human lung cancer cell line (NCI-H460) xenograft mice.
- NCI-H460 human lung cancer cell line
- a group receiving saline intraperitoneal administration was set as a control group, and a group receiving a combination administration of the recombinant vaccinia virus (WOTS-418, 1 ⁇ 10 7 pfu) and hydroxyurea (30 mg/kg) was set as an experimental group.
- Recombinant vaccinia virus was administered intraperitoneally once, and hydroxyurea was administered intraperitoneally 6 times/week, excluding the day of administration of the recombinant vaccinia virus from 1 day before administration to 15 days after administration of the recombinant vaccinia virus.
- mice Female, 7 weeks sold in Orient Bio (Busan) were subjected to an adaptation period of 2 days and then a mouse colon cancer cell line of 1 ⁇ 10 6 cells (CT-26, Korea Cell Line Bank). Was avoided. After 7 days, administration of recombinant vaccinia virus (WOTS-418) and hydroxyurea was started. On the other hand, the recombinant vaccinia virus (WOTS-418) derived from Western Reserve species has a stronger proliferation power in an allograft model than the recombinant vaccinia virus derived from Wyeth species.
- Recombinant vaccinia virus (WOTS-418, 1 ⁇ 10 7 pfu) was administered intraperitoneally, and recombinant vaccinia virus and hydroxyurea (30 mg/kg) were co-administered.
- Recombinant vaccinia virus was administered intraperitoneally once, and hydroxyurea was administered intraperitoneally for 5 consecutive times from 1 day after administration of the recombinant vaccinia virus.
- Balb/c mice female, 7 weeks sold in Orient Bio (Busan) were allografted to Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a 2-day adaptation period. ) was performed. After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus was started.
- the group receiving saline intratumoral administration was set as the negative control group, and the group receiving the recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) was set as the positive control group.
- the group receiving the recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) and the recombinant human granulocyte colony-stimulating factor (rh-G-CSF, 75 ⁇ g/kg) The group receiving the overrecombinant virus (Wyeth VV tk-, 1 ⁇ 10 7 pfu) and hydroxyurea (30 mg/kg) was set as the experimental group.
- Recombinant vaccinia virus was administered intratumorally, and rh-G-CSF or hydroxyurea was administered intraperitoneally from 3 days before administration of the recombinant vaccinia virus to 5 times/week before sacrifice.
- mice of each group of Experimental Example 7.1 were sacrificed on the 16th day after administration of the drug to measure the size of the tumor.
- the positive control mice and mice in the experimental group receiving the combination administration of recombinant vaccinia virus and rh-G-CSF increased about 10 times from the initial tumor size.
- the mice in the experimental group receiving the combined administration of the recombinant vaccinia virus and hydroxyurea decreased the initial tumor size by about 8 times, and the tumor size was observed to be the most suppressed (FIG. 8).
- each group of mice was sacrificed on the 16th day of Experimental Example 7.1, and then lymphocyte cells in the spleen were separated for each group. Thereafter, the isolated lymphocyte cells were injected into each new normal mouse, and cancer was implanted to observe the size of the tumor.
- an allograft was performed with a Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells, and the size of the tumor was measured on the 19th day.
- mice injected with splenocytes collected from mice of the group receiving the combined administration of recombinant vaccinia virus and hydroxyurea were remarkably suppressed in mice injected with splenocytes collected from mice of the group receiving the combined administration of recombinant vaccinia virus and hydroxyurea.
- tumor growth was not significantly suppressed in the mice injected with splenocytes collected from the remaining mice, respectively (FIG. 9).
- immune cells such as cytotoxic T cells were formed in the group administered with the recombinant vaccinia virus and hydroxyurea in combination, as well as activating the adaptive immunity.
- mice female, 7 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after 7 days adaptation period. I did. The tumor was observed until the size of the tumor reached 50 mm 3 to 100 mm 3 and then the recombinant vaccinia virus was administered.
- Wyeth species-derived recombinant vaccinia virus Wyeth VV tk- ) hardly proliferates in a mouse renal cancer cell-embedded mouse model.
- the group receiving saline intratumoral administration was set as the negative control group, and the group receiving only hydroxyurea (30 mg/kg) and the group receiving only recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) were positive. It was set as a control.
- a group receiving co-administration of recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) and hydroxyurea (30 mg/kg) was set as the experimental group.
- Recombinant vaccinia virus was administered intratumorally, and hydroxyurea was administered intraperitoneally from 3 days before administration of the recombinant vaccinia virus to 5 times/week before sacrifice.
- tumor sizes were measured on the 0th, 4th, 10th, 15th and 22nd days.
- the tumor size of the positive control mice increased about 11 to 13 times compared to the initial tumor size.
- the tumor size of the mice in the experimental group was increased by about 4 times compared to the size of the initial tumor (FIG. 10).
- each group of mice was sacrificed on the 16th day of Example 8.1, and then splenocytes and cytotoxicity were performed for each group.
- T lymphocyte (CD8+ T cell) cells were isolated. Then, the isolated splenocytes or cytotoxic T lymphocyte cells were injected into new normal mice, respectively, and cancer was implanted to observe the size of the tumor.
- allograft was performed with a Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells, and the size of the tumor was measured on the 7th, 10th, 14th, 18th and 21st days.
- mice female, 8 weeks sold in Orient Bio (Busan) were allografted with a Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a 7-day adaptation period. I did. The tumor was observed until the size of the tumor reached 100 mm 3 to 150 mm 3 , and then the recombinant vaccinia virus was administered. On the other hand, Wyeth species-derived recombinant vaccinia virus (Wyeth VV tk- ) hardly proliferates in a mouse renal cancer cell-embedded mouse model.
- Wyeth species-derived recombinant vaccinia virus Wyeth species-derived recombinant vaccinia virus (Wyeth VV tk- ) hardly proliferates in a mouse renal cancer cell-embedded mouse model.
- the group receiving saline intratumoral administration was used as the negative control group, and the group receiving the recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) was set as the positive control group.
- recombinant vaccinia virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) and hydroxyurea (30 mg/kg) were administered as experimental groups.
- Recombinant vaccinia virus was administered intratumorally, and hydroxyurea was administered intraperitoneally from 1 day before administration of recombinant vaccinia virus to 6 times/week before sacrifice.
- the tumor was sacrificed on the 22nd day to measure the size of the tumor.
- the tumor size of the positive control mice was suppressed by about 25% compared to the tumor size of the negative control mice.
- the tumor size of the mice in the experimental group was suppressed by about 37.5% compared to that of the mice in the negative control group, and about 15% more than the tumor size in the mice in the positive control group (Fig. 13).
- the distribution of immune cells in the tumor microenvironment was analyzed when the recombinant vaccinia virus and hydroxyurea were co-administered.
- immunohistochemical staining using DAB Diaminobenzidine was performed. Specifically, the spleen of each group of mice was collected, the spleen tissue was cut to 0.4 ⁇ m, and dried. Thereafter, the tissue was washed with PBS and treated with bovine serum albumin (BSA), and primary antibodies (anti-CD3 antibody (Abcam), anti-CD4 antibody (BD Biosciences), anti-CD8 antibody (BD Biosciences)) were prepared. Diluted in a ratio of 1:50, the tissue was treated and reacted at 4°C overnight.
- BSA bovine serum albumin
- primary antibodies anti-CD3 antibody (Abcam), anti-CD4 antibody (BD Biosciences), anti-CD8 antibody (BD Biosciences)
- mice 4T1(I)
- mice female, 7 weeks sold in Orient Bio (Busan) were allografted with a 4T1 cancer cell line (Korea Cell Line Bank) of 1 ⁇ 10 6 cells after a 7-day adaptation period. I did. The tumor was observed until the size of the tumor reached 100 mm 3 to 150 mm 3 , and then the recombinant vaccinia virus was administered. On the other hand, Wyeth species-derived recombinant vaccinia virus (OTS-412) rarely proliferates in a breast cancer cell line-embedded mouse model.
- the breast cancer cell line-embedded mouse is an animal model in which metastasis to the whole body including lung tissue progresses, and metastasis is generally evaluated by the number of nodules on the tumor surface.
- a group receiving saline intratumoral administration was set as a negative control group, and a group receiving recombinant vaccinia virus (OTS-412, 1 ⁇ 10 7 pfu) or hydroxyurea (30 mg/kg) was used as a positive control group.
- a group that co-administered recombinant vaccinia virus and hydroxyurea was set as the experimental group.
- Recombinant vaccinia virus was administered for the second time on day 7 after the first intratumoral administration. Hydroxyurea was administered intraperitoneally once a day, excluding the day of administration of the recombinant vaccinia virus from 3 days before administration of the recombinant vaccinia virus to 3 days before sacrifice.
- mice of each group were sacrificed, blood and spleen were collected, and the distribution of immune cells in the blood and in the splenocytes was analyzed by flowcytometry. As a result, it was confirmed that the distribution of CD4+ T cells and CD8+ T cells that induce tumor immune responses in blood and spleen was highest in the experimental mice. In addition, it was confirmed that myeloid derived suppressor cells (MDSC), which have an immunosuppressive function, were significantly lower in the experimental group mice than in the negative and positive control mice (FIG. 15).
- MDSC myeloid derived suppressor cells
- mice Female, 10 weeks sold in Orient Bio (Busan) were subjected to an adaptation period of 2 days, and then a 4T1 cancer cell line (Korea Cell Line Bank) of 1 ⁇ 10 6 cells was placed on the left thigh. Two days later, the same number of 4T1 cancer cell lines were applied to the right thigh. After observing until the size of the subcutaneous tumor on the left thigh reached 50 mm 3 to 200 mm 3 , administration of the recombinant vaccinia virus was started.
- 4T1 cancer cell line Korea Cell Line Bank
- a group receiving saline intraperitoneally was set as a negative control group, and a group receiving recombinant vaccinia virus (WR VV tk- , 1 ⁇ 10 5 pfu) was set as a positive control group.
- the group receiving the combined administration of the recombinant vaccinia virus and hydroxyurea was set as the experimental group.
- Recombinant vaccinia virus was administered once into the left tumor, and hydroxyurea was administered intraperitoneally 6 times/week, excluding the day of administration of the recombinant vaccinia virus from 1 day before administration to 14 days after administration of the recombinant vaccinia virus.
- the size of tumors implanted subcutaneously on both thighs on the 0th, 3rd, 7th, 10th and 14th days after administration of the drug to the mice of each group was measured.
- the size of the left tumor of the mice in the experimental group was inhibited by about 35% of the size of the left tumor of the mice in the positive control group (FIG. 16).
- the size of the right tumor of the mice in the experimental group was inhibited by about 45% of the size of the right tumor of the positive control group (FIG. 17).
- mice female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of wild-type Western Reserve species vaccinia virus (WR) was started. On the other hand, the wild-type Western Reserve species vaccinia virus has limited proliferation in syngeneic mice.
- the group receiving saline intraperitoneally was set as the negative control group, and the group receiving wild-type vaccinia virus (WR, 1 ⁇ 10 7 pfu) was set as the positive control group.
- the group receiving the combined administration of the wild-type vaccinia virus and hydroxyurea 60 mg/kg was set as the experimental group. Wild-type vaccinia virus was administered intraperitoneally twice, and hydroxyurea was administered intraperitoneally 6 times/week, excluding the day of administration of wild-type vaccinia virus from 1 day before administration to 21 days after administration of wild-type vaccinia virus.
- mice of each group were sacrificed on the 22nd day, tumors were isolated from the mice, and virus proliferation was compared through immunohistochemical staining using DAB (Diaminobenzidine). Specifically, the tumor tissue of each group of mice was collected, the tumor tissue was cut to 0.4 ⁇ m, and dried. Thereafter, the tissues were washed with PBS, treated with bovine serum albumin (BSA), and treated with a primary antibody (Cat No. ABIN1606294, Antibodies-Online) at a ratio of 1:50 to the tissues and treated overnight at 4°C. Reacted. The next day, after washing the tissue with PBS, a secondary antibody (Alexa 594, Cat no. A21205, Invitrogen) was reacted at room temperature for 30 minutes. After the tissue was washed with PBS again, the reaction was performed using an ABC kit (Dako), and H 2 O 2 was added to develop color, followed by a dehydration process and then encapsulated.
- DAB Diaminobenzidine
- mice Female, 7 weeks distributed from Orient Bio (Busan) were subjected to an adaptation period of 2 days, and then the administration of wild-type Western Reserve species vaccinia virus (WR) was started.
- the wild-type Western Reserve species vaccinia virus has limited proliferation in syngeneic mice.
- the group receiving the wild-type western reserve species vaccinia virus (1 ⁇ 10 7 pfu) was set as a control group, and the group receiving the wild-type western reserve species vaccinia virus and hydroxyurea (50 mg/kg) in combination was set as the experimental group.
- mice of the control group and the experimental group were sacrificed to separate kidney tissue and liver tissue, and immunohistochemical staining was performed. After making a paraffin block, deparaffinization was performed using xylene and ethyl alcohol. After going through an antigen retrieval using a decloaking chamber, a primary antibody (Cat no.ABIN1606294, Antibodies-Online) is attached and a FITC-labeled secondary antibody (Alexa 594, Cat no.A21205) is applied. , Invitrogen) was attached and observed using a fluorescence microscope.
- a primary antibody Cat no.ABIN1606294, Antibodies-Online
- a FITC-labeled secondary antibody Alexa 594, Cat no.A21205
- mice female, 7 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after 7 days adaptation period. I did. After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus was started. On the other hand, recombinant vaccinia virus (OTS-412) hardly proliferates in a mouse renal cancer cell-embedded mouse model.
- OTS-412 recombinant vaccinia virus
- the group receiving saline intratumoral administration was set as the negative control group, and the group receiving hydroxyurea (30 mg/kg) was set as the positive control group.
- Recombinant vaccinia virus (OTS-412, 1 ⁇ 10 7 pfu) receiving group recombinant vaccinia administration of California virus (OTS-412, 1 ⁇ 10 7 pfu) and recombinant human granulocyte population stimulating factor (Recombinant human granulocyte colony-stimulating factor, rh-G-CSF, 75 ⁇ g/kg) and the group receiving recombinant vaccinia virus (OTS-412, 1 ⁇ 10 7 pfu) and hydroxyurea (30 mg/kg) as experimental groups.
- Recombinant vaccinia virus was administered intratumorally, and the second was administered 13 days after the first administration.
- rh-G-CSF or hydroxyurea was administered intraperitoneally from 2 days before administration of the recombinant vaccinia virus until sacrifice.
- mice female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of the recombinant vaccinia virus was started. On the other hand, the recombinant vaccinia virus (WR VV tk- ) is capable of proliferation in a mouse model of mouse renal cancer cell implantation.
- Recombinant vaccinia virus was administered intraperitoneally twice, and hydroxyurea was administered intraperitoneally 6 times/week, excluding the day of administration of the recombinant vaccinia virus from 1 day before administration to 21 days after administration of the recombinant vaccinia virus.
- mice Female renal cancer cell implantation Confirmation of absolute neutrophil count (ANC) when co-administration of recombinant vaccinia virus (WOTS-418) and hydroxyurea in mice
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of an anticancer virus derived from Western Reserve species vaccinia virus (WOTS-418) was started.
- WOTS-418 Western Reserve species vaccinia virus
- the group administered saline intraperitoneally was the negative control group
- the group administered the anticancer virus (WOTS-418, 1 ⁇ 10 7 pfu) was the positive control group
- the group treated with the anticancer virus and hydroxyurea (30 mg/kg) at the same time. It was set as an experimental group.
- the anticancer virus was administered intraperitoneally once, and hydroxyurea was administered intraperitoneally every day from 1 day before the anticancer virus administration to the 2nd day after administration.
- mice of each group were sacrificed to perform a general blood count (CBC), and as a result, it was confirmed that the neutrophil count of the mice in the experimental group was lowered (FIG. 22).
- CBC general blood count
- mice in each group were sacrificed and a general blood count (CBC) was performed.
- CBC general blood count
- the neutrophil count of the mice in the lenalidomide group was more than one. It was confirmed that the value was lower than that of the saline-administered group, except for chi.
- the neutrophil levels of the mice in the group administered with hydroxyurea were significantly lower than in the group administered with saline solution (FIG. 23).
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , administration of an anticancer virus derived from Western Reserve species vaccinia virus (WOTS-418) was started.
- WOTS-418 Western Reserve species vaccinia virus
- the group administered saline intraperitoneally was the negative control group
- the group administered the anticancer virus (WOTS-418, 1 ⁇ 10 7 pfu) was the positive control group
- the group administered the combination of anticancer virus and hydroxyurea (30 mg/kg)
- the group that co-administered anticancer virus and lenalidomide (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered intraperitoneally once, and hydroxyurea or lenalidomide was administered intraperitoneally from 1 day before the anticancer virus administration to the 2nd day after administration.
- mice of each group were sacrificed and a general blood count (CBC) was performed.
- CBC general blood count
- mice Female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , anticancer virus administration was started. On the other hand, Western Reserve species vaccinia virus-derived anti-cancer virus (WR VV tk- ) is capable of proliferation in a mouse model of mouse renal cancer cell implantation.
- the group administered saline intraperitoneally was set as the control group, the group administered with the anticancer virus (WR VV tk- , 1 ⁇ 10 7 pfu) alone, the group administered with the anticancer virus and hydroxyurea (60 mg/kg) in combination ,
- An experiment was performed by dividing the anticancer virus and lenalidomide (25 mg/kg) into groups administered concurrently.
- the anticancer virus was administered intraperitoneally twice, and hydroxyurea or lenaridomide was administered intraperitoneally 6 times/week, excluding the day of administration of the anticancer virus from 1 day before the anticancer virus administration to the 21st day after administration.
- the group administered with the anticancer virus alone inhibited tumor growth statistically significantly compared to the control group (p ⁇ 0.001).
- the group administered with anticancer virus and lenalidomide showed a tendency to inhibit tumor growth compared to the group administered with lenalidomide alone.
- the group administered with anticancer virus and hydroxyurea significantly inhibited tumor growth compared to the group administered with anticancer virus alone (p ⁇ 0.05), and the group administered with lenalidomide and hydroxyurea was observed. It was confirmed that tumor growth was more inhibited than in the group administered with the anticancer virus and hydroxyurea in combination (FIG. 25).
- mice Female, 8 weeks sold in Orient Bio (Busan) were allografted with Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after a week of adaptation period. . After observing until the tumor size reached 100 mm 3 to 150 mm 3 , anticancer virus administration was started. On the other hand, Western Reserve species vaccinia virus-derived anti-cancer virus (WOTS-418) can be proliferated in a mouse model of mouse renal cancer cell implantation.
- WOTS-418 Western Reserve species vaccinia virus-derived anti-cancer virus
- the group administered saline intraperitoneally was set as the control group, the group administered with the anticancer virus (WR VV tk- , 1 ⁇ 10 7 pfu) alone, the group administered with the anticancer virus and hydroxyurea (60 mg/kg) in combination ,
- An experiment was performed by dividing the anticancer virus and palbociclib (50 mg/kg, 100 mg/kg) into groups administered concurrently.
- Anticancer virus was administered intraperitoneally once, palbociclib was orally administered once/day from 5 days before anticancer virus administration, and hydroxyurea was administered with anticancer virus from 1 day before anticancer virus administration until 19 days after administration. Excluding the day, it was administered intraperitoneally 6 times/week.
- mice were measured on the 3rd, 6th, 9th, 12th, 16th and 19th days after administration of each drug to the control group and each group of Experimental Example 20.1. As a result, there was no tendency to lose weight in all co-administration groups, and there was a tendency that the body weight continued to decrease in the group administered with the anticancer virus alone, but the body weight on the 19th day was 90% compared to the body weight at the start of administration. It was confirmed that the safety was not at a level of concern because it was kept close (FIG. 27).
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted to Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after 7 days adaptation period. was performed. After observing until the tumor size reached 200 mm 3 to 300 mm 3 , administration of anticancer virus (Wyeth VV tk- ) was started. The anticancer virus has limited proliferation in an allograft model.
- the group receiving saline intraperitoneally was set as the negative control group
- the group receiving the mouse PD-1 inhibitor the group receiving the anticancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) intratumoral administration
- tk- , 1 ⁇ 10 7 pfu) and PD-1 inhibitor co-administration group was set as a positive control group.
- a group receiving co-administration of anti-cancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu), PD-1 inhibitor and hydroxyurea (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered once intratumorally, the PD-1 inhibitor was administered intraperitoneally on the 14th, 16th, 18th and 20th days once every 2 days, and hydroxyurea was administered intraperitoneally 6 times/week. .
- tumor sizes were measured on the 0th, 4th, 10th, 14th, 17th and 21st days. As a result, it was confirmed that the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 28).
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted to Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after 7 days adaptation period. was performed. After the tumor was observed until the size of the tumor reached 50 mm 3 to 150 mm 3 , administration of anticancer virus (Wyeth VV tk- ) was started. The anticancer virus has limited proliferation in an allograft model.
- the group receiving saline intraperitoneally was set as the negative control group
- the group receiving the CTLA-4 inhibitor the group receiving the anti-cancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) intratumorally
- - , 1 ⁇ 10 7 pfu) and CTLA-4 inhibitor co-administration group was set as a positive control group.
- a group receiving co-administration of anti-cancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu), CTLA-4 inhibitor and hydroxyurea (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered once intratumorally
- the CTLA-4 inhibitor was administered intraperitoneally on the 3rd, 5th, 7th and 9th days once every 2 days, and hydroxyurea was administered intraperitoneally 6 times/week. .
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted into Renca cancer cell line (Korea Cell Line Bank) of 5 ⁇ 10 6 cells after 7 days adaptation period. was performed. After the tumor was observed until the size of the tumor reached 50 mm 3 to 100 mm 3 , administration of anticancer virus (Wyeth VV tk- ) was started. The anticancer virus has limited proliferation in an allograft model.
- the group receiving saline intraperitoneally was set as the negative control group, the group receiving the PD-L1 inhibitor (300 ⁇ g/mouse), the group receiving the anticancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) intratumorally,
- a group receiving co-administration of cancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu) and PD-L1 inhibitor was set as a positive control group.
- a group administered with both cancer virus (Wyeth VV tk- , 1 ⁇ 10 7 pfu), PD-L1 inhibitor and hydroxyurea (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered once in the tumor, and the PD-L1 inhibitor was administered intraperitoneally on days 0, 3, 7, 10, 14, 17 and 21, and hydroxyurea was administered 6 times/ It was administered intraperitoneally for the week.
- tumor sizes were measured on the 0th, 3rd, 7th, 10th, 14th, 17th and 21st days.
- the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 30).
- the experimental group was about 46% smaller than the group receiving the combination administration of the anticancer virus and the PD-L1 inhibitor.
- mice Female, 8 weeks sold in Orient Bio (Busan) were allografted into a 4T1 cancer cell line (Korea Cell Line Bank) of 1 ⁇ 10 6 cells after a 7-day adaptation period. was performed. After the tumor was observed until the size of the tumor reached 50 mm 3 to 150 mm 3 , administration of anticancer virus (WR VV tk- ) was started.
- the anti-cancer virus (WR VV tk- ) derived from the Western Reserve species vaccinia virus has a stronger proliferative power in the allograft model than the anti-cancer virus derived from the Wyeth species vaccinia virus.
- a group receiving saline intraperitoneally was set as a negative control group, a group receiving a CTLA-4 inhibitor (300 ⁇ g/mouse), a group receiving an anticancer virus (WR VV tk- , 1 ⁇ 10 7 pfu) intratumorally,
- the group receiving co-administration of anti-cancer virus (WR VV tk- , 1 ⁇ 10 7 pfu) and CTLA-4 inhibitor was set as a positive control group.
- a group receiving co-administration of anticancer virus (WR VV tk- , 1 ⁇ 10 7 pfu), CTLA-4 inhibitor and hydroxyurea (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered intraperitoneally twice
- the CTLA-4 inhibitor was administered intraperitoneally on the 3rd, 5th, 7th and 9th days
- hydroxyurea was administered intraperitoneally 6 times/week.
- mice 4T1(II)
- Balb/c mice female, 8 weeks sold in Orient Bio (Busan) were allografted into a 4T1 cancer cell line (Korea Cell Line Bank) of 1 ⁇ 10 6 cells after a 7-day adaptation period. was performed. After observing until the tumor size reached 50 mm 3 to 100 mm 3 , administration of an anticancer virus derived from Western Reserve species vaccinia virus (WOTS-418) was started. Western Reserve species are more proliferative in allograft models than Wyeth species.
- the group receiving saline intraperitoneally was set as the negative control group, the group receiving the PD-L1 inhibitor (300 ⁇ g/mouse), the group receiving the anti-cancer virus (WOTS-418, 1 ⁇ 10 7 pfu) intratumoral administration, and the anti-cancer group.
- a group receiving co-administration of virus (WOTS-418, 1 ⁇ 10 7 pfu) and PD-L1 inhibitor was set as a positive control group.
- a group administered with all anticancer virus (WOTS-418, 1 ⁇ 10 7 pfu), PD-L1 inhibitor, and hydroxyurea (30 mg/kg) was set as the experimental group.
- the anticancer virus was administered intraperitoneally twice, the PD-L1 inhibitor was administered intraperitoneally on the 3rd, 5th, 7th and 9th days, and hydroxyurea was administered intraperitoneally 6 times/week.
- tumor sizes were measured on the 0th, 3rd, 7th, 10th and 14th days.
- the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 32).
- the experimental group was about 30% smaller than that of the group receiving the combination administration of the anticancer virus and the PD-L1 inhibitor.
- the survival rate for 30 days of mice in each group of Experimental Example 5.1 was analyzed. As a result, it was confirmed that the survival rate of the mice in the experimental group was higher than that of the mice in the negative control group and the positive control group.
- mice Mouse colon cancer cell implantation Analysis of survival rate of anti-cancer virus (WR, WOTS-418), PD-L1 inhibitor, and hydroxyurea in mice: CT-26 I
- mice sold in Orient Bio were subjected to an adaptation period of 7 days, and then a mouse colon cancer (CT-26) cell line (Korea Cell Line Bank) of 1 ⁇ 10 6 cells was subcutaneously used. I did. After 7 days, anticancer virus (WR) and PD-L1 inhibitor were administered intraperitoneally, and hydroxyurea was administered daily for 5 days from the next day.
- CT-26 mouse colon cancer
- WR anticancer virus
- PD-L1 inhibitor were administered intraperitoneally, and hydroxyurea was administered daily for 5 days from the next day.
- Western Reserve species vaccinia virus has a stronger proliferative power in an allograft model than vaccinia virus Wyeth strain.
- the group receiving saline intraperitoneal administration was set as the negative control group, the group receiving the PD-L1 inhibitor (200 ⁇ g/mouse) alone, and the anticancer virus (WOTS-418) and hydroxyurea (30 mg/kg) concurrently administered.
- the receiving group was set as a positive control group.
- a group receiving co-administration of anticancer virus (WR, 1 ⁇ 10 6 pfu or WOTS-418, 1 ⁇ 10 7 pfu), PD-L1 inhibitor and hydroxyurea was set as the experimental group.
- the anticancer virus was administered intraperitoneally once
- the PD-L1 inhibitor was administered intraperitoneally on the 1st, 4th, 8th and 11th days
- hydroxyurea was administered intraperitoneally 5 times/week.
- mice in the experimental group had the longest survival period compared to the mice in the negative control group and the mice in the positive control group. It was confirmed that the safety was improved.
- the group receiving saline intraperitoneally was set as the negative control group, and the group receiving the combination administration of Western Reserve species vaccinia virus (WR, 1 ⁇ 10 5 pfu) and hydroxyurea (30 mg/kg) and Western Reserve species vaccinia
- the group receiving the virus and CTLA-4 inhibitor (150 ⁇ g/mouse) was set as a positive control group.
- a group receiving the Western Reserve species vaccinia virus, CTLA-4 inhibitor, and hydroxyurea was set as the experimental group.
- Western Reserve species vaccinia virus was administered intraperitoneally once, CTLA-4 inhibitor was administered intraperitoneally on days 2, 4, 6 and 8, and hydroxyurea was administered intraperitoneally 4 times/week. .
- the tumor size was measured on the 0th, 3rd and 7th days after administration of the drug to the mice of each group. As a result, it was confirmed that the tumor size of the mice in the experimental group was significantly suppressed compared to the tumor size of the mice in the positive control group (FIG. 33).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (30)
- 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 백시니아 바이러스는 웨스턴 리저브(Western Reserve, WR), NYVAC(New York Vaccinia Virus), Wyeth(The New York City Board of Health; NYCBOH), LC16m8, 리스터(Lister), 코펜하겐(Copenhagen), 티안탄(Tian Tan), USSR, 타쉬켄트(TashKent), 에반스(Evans), IHD-J(International Health Division-J) 또는 IHD-W(International Health Division-White) 백시니아 바이러스 종(strain)인 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 백시니아 바이러스가 야생형 백시니아 바이러스 또는 재조합 백시니아 바이러스인 것인, 암 치료용 약학 조성물.
- 제 3항에 있어서,상기 재조합 백시니아 바이러스는 야생형 백시니아 바이러스 유전자 중 적어도 하나가 결실되거나, 외래 유전자가 삽입된 것인, 암 치료용 약학 조성물.
- 제 4항에 있어서,상기 야생형 백시니아 바이러스의 유전자는 티미딘 키나아제(thymidine kinase) 유전자, 백시니아 성장인자(vaccinia growth factor) 유전자, F13.5L 유전자, F14.5 유전자, A56R 유전자, B18R 유전자 또는 이들의 조합으로 이루어진 군으로부터 선택되는 어느 하나인 것인, 암 치료용 약학 조성물.
- 제 4항에 있어서,상기 외래 유전자는 HSV-TK(Herpes simplex virus thymidine kinase), 변이된 HSV-TK, GM-CSF(granulocyte-macrophage colony-stimulating factor), CD(cytosin deaminase), 카르복실에스테라아제(carboxyl esterase) 1형, 카르복실에스테라아제 2형, INF-β(Interferone beta), 소마토스타틴 수용체 2(somatostatin receptor 2) 및 이들의 조합으로 이루어진 군으로부터 선택되는 어느 하나를 코딩하는 유전자인 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 암은 폐암, 대장암, 전립선암, 갑상선암, 유방암, 뇌암, 두경부암, 식도암, 피부암, 흉선암, 위암, 결장암, 간암, 난소암, 자궁암, 방광암, 직장암, 담낭암, 담도암, 췌장암 및 이의 조합으로 이루어진 군으로부터 선택되는 어느 하나인 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 과립백혈구 형성 억제제는 히드록시유레아(hydroxyurea), 레날리도마이드(Lenalidomide), 탈리도마이드(thalidomide), 타다라필(Tadalafil), 팔보시클립(palbociclib), 알킬화제(Alkylating agents), 안트라사이클린(Anthracyclines), 대사길항제(Antimetabolites), 캄토테신(Camptothecins), 에피포도필로톡신(Epipodophyllotoxins), 마이토마이신C(Mitomycin C), 탁센(Taxanes) 또는 빈블라스틴(Vinblastine)인 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 과립백혈구가 호중구인 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 조성물이 면역관문억제제를 추가적으로 포함하는 것인, 암 치료용 약학 조성물.
- 제 1항에 있어서,상기 암 치료용 약학 조성물은 상기 백시니아 바이러스의 암 선택성이 증가된 것을 특징으로 하는 것인, 암 치료용 약학 조성물.
- 백시니아 바이러스를 유효성분으로 포함하는 제1조성물 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 제2조성물을 포함하는 암 예방 또는 치료용 키트.
- 제 12항에 있어서,상기 키트가 면역관문억제제를 유효성분으로 포함하는 제3조성물을 추가적으로 포함하는 것인, 암 예방 또는 치료용 키트.
- 암이 발병된 개체에 과립백혈구 형성 및 백시니아 바이러스를 투여하는 단계를 포함하는 암 치료방법.
- 상기 치료방법이 암이 발병된 개체에 면역관문억제제를 투여하는 단계를 추가적으로 포함하는 것인, 암 치료방법.
- 제 14항에 있어서,상기 백시니아 바이러스 및 상기 과립백혈구 형성 억제제가 동시, 순차적, 또는 역순으로 병용 투여되는 것을 특징으로 하는, 암 치료방법.
- 제 14항에 있어서,상기 과립백혈구 형성 억제제가 백시니아 바이러스 투여 전, 중 또는 후에 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 과립백혈구 형성 억제제가 백시니아 바이러스 투여 3일 내지 5일 전, 백시니아 바이러스 투여 후, 1일 1회, 9일 내지 28일 동안 연속적으로 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 과립백혈구 형성 억제제가 10 ㎎/㎏/day 내지 90 ㎎/㎏/day 용량으로 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 백시니아 바이러스가 1Х105 pfu 내지 1Х1010 pfu 용량으로 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 백시니아 바이러스가 7일 내지 30일 간격으로 개체에 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 과립백혈구 형성 억제제가 종양 내, 복강 내 또는 정맥 내로 투여되는 것인, 암 치료방법.
- 제 14항에 있어서,상기 백시니아 바이러스가 종양 내, 복강 내 또는 정맥 내로 투여되는 것인, 암 치료방법.
- 암을 예방 또는 치료하기 위한 백시니아 바이러스 및 과립백혈구 형성 억제제를 포함하는 조성물의 용도.
- 암의 예방 또는 치료용 약제를 제조하기 위한 백시니아 바이러스 및 과립백혈구 형성 억제제를 포함하는 조성물의 용도.
- 과립백혈구 형성 억제제를 유효성분으로 포함하는 항암보조제.
- 제 26항에 있어서,상기 항암보조제는 백시니아 바이러스를 유효성분으로 포함하는 항암제의 항암보조제로서 사용되는 것을 특징으로 하는 것인, 항암보조제.
- 제 26항에 있어서,상기 항암보조제는 백시니아 바이러스의 항암활성을 개선, 향상 또는 증대시키는 것을 특징으로 하는 것인, 항암보조제.
- 제 26항에 있어서,상기 항암보조제는 백시니아 바이러스의 암 선택성을 증가시키는 것을 특징으로 하는 것인, 항암보조제.
- 제 26항에 있어서,상기 과립백혈구 형성 억제제가 히드록시유레아(hydroxyurea), 레날리도마이드(Lenalidomide), 탈리도마이드(thalidomide), 타다라필(Tadalafil), 팔보시클립(palbociclib) 알킬화제(Alkylating agents), 안트라사이클린(Anthracyclines), 대사길항제(Antimetabolites), 캄토테신(Camptothecins), 에피포도필로톡신(Epipodophyllotoxins), 마이토마이신C(Mitomycin C), 탁센(Taxanes) 또는 빈블라스틴(Vinblastine)인 것인, 항암보조제.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080076652.7A CN114630683A (zh) | 2019-08-29 | 2020-08-31 | 包含痘苗病毒和粒细胞生成抑制剂作为活性成分的用于治疗癌症的药物组合物 |
JP2022509096A JP2022545191A (ja) | 2019-08-29 | 2020-08-31 | 活性成分としてワクシニアウイルス及び顆粒球生成阻害剤を含む、がん治療用医薬組成物 |
AU2020337054A AU2020337054A1 (en) | 2019-08-29 | 2020-08-31 | Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients |
CA3152973A CA3152973A1 (en) | 2019-08-29 | 2020-08-31 | Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients |
US17/638,750 US20220288143A1 (en) | 2019-08-29 | 2020-08-31 | Pharmaceutical composition for treating cancer, comprising vaccinia virus and granulopoiesis inhibitor as active ingredients |
EP20859414.3A EP4023235A4 (en) | 2019-08-29 | 2020-08-31 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER WITH VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20190106736 | 2019-08-29 | ||
KR10-2019-0106736 | 2019-08-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021040496A1 true WO2021040496A1 (ko) | 2021-03-04 |
Family
ID=74685712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/011648 WO2021040496A1 (ko) | 2019-08-29 | 2020-08-31 | 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220288143A1 (ko) |
EP (1) | EP4023235A4 (ko) |
JP (1) | JP2022545191A (ko) |
KR (1) | KR102661908B1 (ko) |
CN (1) | CN114630683A (ko) |
AU (1) | AU2020337054A1 (ko) |
CA (1) | CA3152973A1 (ko) |
WO (1) | WO2021040496A1 (ko) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120114612A1 (en) * | 2009-07-10 | 2012-05-10 | Evans David H | Oncolytic Viruses And Methods For Treating Neoplastic Disorders |
KR20140123436A (ko) * | 2013-04-10 | 2014-10-22 | 신라젠(주) | 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 hbb301 |
KR20190080806A (ko) * | 2017-12-28 | 2019-07-08 | 주식회사 바이오녹스 | 안전성 및 항암효과가 개선된 종양 용해 바이러스 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101772375B1 (ko) * | 2005-09-07 | 2017-08-29 | 신라젠(주) | Gm-csf를 발현하는 폭스바이러스를 사용한 전이성 및/또는 전신 파종성 암의 전신 치료법 |
EP2073823A1 (en) * | 2006-10-13 | 2009-07-01 | Medigene AG | Use of oncolytic viruses and antiangiogenic agents in the treatment of cancer |
KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
CN104427992B (zh) * | 2012-01-25 | 2017-12-19 | 德那翠丝有限公司 | 生物标志物及使用溶瘤病毒和免疫调节剂的组合疗法 |
WO2017205674A1 (en) * | 2016-05-25 | 2017-11-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic vaccinia virus mutants and using same for cancer treatment |
AU2017332367B2 (en) * | 2016-09-21 | 2021-12-23 | Stephen H. Thorne | High mobility group box i mutant |
TW202015720A (zh) * | 2018-06-19 | 2020-05-01 | 美商尼恩醫療公司 | 新抗原及其用途 |
US20220304960A1 (en) * | 2019-08-26 | 2022-09-29 | Bionoxx Inc. | Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer |
AU2019464086A1 (en) * | 2019-08-26 | 2022-02-24 | Bionoxx Inc. | Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients |
-
2020
- 2020-08-31 US US17/638,750 patent/US20220288143A1/en active Pending
- 2020-08-31 AU AU2020337054A patent/AU2020337054A1/en active Pending
- 2020-08-31 KR KR1020200110574A patent/KR102661908B1/ko active IP Right Grant
- 2020-08-31 WO PCT/KR2020/011648 patent/WO2021040496A1/ko unknown
- 2020-08-31 JP JP2022509096A patent/JP2022545191A/ja active Pending
- 2020-08-31 CN CN202080076652.7A patent/CN114630683A/zh active Pending
- 2020-08-31 EP EP20859414.3A patent/EP4023235A4/en active Pending
- 2020-08-31 CA CA3152973A patent/CA3152973A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120114612A1 (en) * | 2009-07-10 | 2012-05-10 | Evans David H | Oncolytic Viruses And Methods For Treating Neoplastic Disorders |
KR20140123436A (ko) * | 2013-04-10 | 2014-10-22 | 신라젠(주) | 백시니아 바이러스로부터 유래한 신규한 항암 바이러스 hbb301 |
KR20190080806A (ko) * | 2017-12-28 | 2019-07-08 | 주식회사 바이오녹스 | 안전성 및 항암효과가 개선된 종양 용해 바이러스 |
Non-Patent Citations (5)
Title |
---|
"GenBank", Database accession no. AAA03056.1 |
ELISABETH HOFMANN;STEPHANIE WEIBEL;ALADAR A SZALAY: "Combination treatment with oncolytic Vaccinia virus and cyclophosphamide results in synergistic antitumor effects in human lung adenocarcinoma bearing mice", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 12, no. 1, 17 July 2014 (2014-07-17), pages 197, XP021194808, ISSN: 1479-5876, DOI: 10.1186/1479-5876-12-197 * |
HEINEMANN LUCY, SIMPSON GUY R, ANNELS NICOLA E, VILE RICHARD, MELCHER ALAN, PRESTWICH ROBIN, HARRINGTON KEVIN J, PANDHA HARDEV S: "The Effect of Cell Cycle Synchronization on Tumor Sensitivity to Reovirus Oncolysis", MOLECULAR THERAPY, NO LONGER PUBLISHED BY ELSEVIER, vol. 18, no. 12, 1 December 2010 (2010-12-01), pages 2085 - 2093, XP055785603, ISSN: 1525-0016, DOI: 10.1038/mt.2010.189 * |
LIAO Y ET AL., PLOS ONE, vol. 8, no. 7, 2013 |
See also references of EP4023235A4 |
Also Published As
Publication number | Publication date |
---|---|
AU2020337054A1 (en) | 2022-03-10 |
CN114630683A (zh) | 2022-06-14 |
KR20210027209A (ko) | 2021-03-10 |
KR102661908B1 (ko) | 2024-04-29 |
US20220288143A1 (en) | 2022-09-15 |
CA3152973A1 (en) | 2021-03-04 |
EP4023235A1 (en) | 2022-07-06 |
EP4023235A4 (en) | 2023-03-29 |
JP2022545191A (ja) | 2022-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018030806A1 (ko) | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 | |
WO2017023138A1 (ko) | 키메라 항원 수용체 및 키메라 항원 수용체가 발현된 t 세포 | |
WO2019182425A1 (ko) | 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도 | |
WO2021107689A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 면역관문 억제제를 포함하는 암 치료용 약학 조성물 | |
WO2011142514A1 (ko) | Pias3을 유효성분으로 포함하는 암 또는 면역질환의 예방 또는 치료용 조성물 | |
WO2020153605A1 (ko) | 메소텔린 특이적인 키메라 항원 수용체 및 이를 발현하는 t 세포 | |
WO2017099474A1 (ko) | GM-CSF 유전자; FLT3L-TRAIL 융합 유전자; TGF-β 발현을 억제하는 shRNA; 및 HSP 발현을 억제하는 shRNA를 포함하는 항종양 조성물 | |
WO2011052883A2 (ko) | Socs2 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법 | |
WO2011115456A2 (ko) | 자가 면역 질환 예방 및 치료용 TNF-α와 TWEAK 이중 길항제 | |
WO2020222461A1 (ko) | 면역항암 보조제 | |
WO2019143201A1 (ko) | 재조합 백시니아 바이러스 및 이를 포함하는 약학 조성물 | |
WO2021040064A1 (ko) | 백시니아 바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물 | |
WO2022025638A1 (ko) | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 | |
WO2021187922A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 항암제를 포함하는 암 치료용 약학 조성물 | |
WO2021040496A1 (ko) | 백시니아 바이러스 및 과립백혈구 형성 억제제를 유효성분으로 포함하는 암 치료용 약학 조성물 | |
WO2019132547A1 (ko) | Chi3l1 억제제를 유효성분으로 하는 암의 폐 전이 예방 또는 치료용 약학 조성물 | |
WO2022145739A1 (en) | Humanized antibody specific for cd22 and chimeric antigen receptor using the same | |
WO2022119380A1 (ko) | 신규한 ace2 변이체 및 그의 이용 | |
WO2022035200A1 (ko) | Il-12 및 항-cd20 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2018026249A1 (ko) | 프로그램화된 세포 사멸 단백질 리간드-1 (pd-l1)에 대한 항체 및 이의 용도 | |
WO2021107635A1 (ko) | Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 nk 세포를 포함하는 항암 치료용 조성물 | |
WO2021040065A1 (ko) | 항암바이러스, 면역관문억제제 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물 | |
WO2022139440A1 (ko) | 신규한 재조합 믹소마바이러스 및 이의 용도 | |
WO2021235685A1 (ko) | 암 예방 또는 치료용 약학적 조성물 | |
WO2019132610A1 (ko) | Baf57 재조합 융합 단백질 및 이의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20859414 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022509096 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3152973 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020337054 Country of ref document: AU Date of ref document: 20200831 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020859414 Country of ref document: EP Effective date: 20220329 |